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Abstract 
 
Development of Au-Immobilized P450 Platform for Exploring the Effect of Oligomer Formation 
on P450-Mediated Metabolism for In Vitro to In Vivo Drug Metabolism Predictions 
 
Lance A. Wollenberg 
Cytochrome P450 (P450) enzymes are a family of oxoferroreductase enzymes containing 
a heme moiety and are well known to be involved in the metabolism of a wide variety of 
endogenous and xenobiotic materials.  It is estimated that roughly 75% of all pharmaceutical 
compounds are metabolized by these enzymes. Traditional reconstituted in-vitro incubation 
studies using recombinant P450 enzymes are often used to predict in-vivo kinetic parameters of a 
drug early in development.  However, in many cases, these reconstituted incubations are prone to 
aggregation which has been shown to affect the catalytic activity of an enzyme.  Moreover, the 
presence of other isoforms of P450 enzymes present in a metabolic incubation, as is the case 
with microsomal systems, may affect the catalytic activity of an enzyme through isoform-
specific protein-protein interactions.  Both of these effects may result in inaccurate prediction of 
in-vivo drug metabolism using in-vitro experiments.    
Here we described the development of immobilized P450 constructs designed to 
elucidate the effects of aggregation and protein-protein interactions between P450 isoforms on 
catalytic activities.  The long term objective of this project is to develop a system to control the 
oligomeric state of Cytochrome P450 enzymes to accurately elucidate discrepancies between in 
vitro reconstituted systems and actual in vivo drug metabolism for the precise prediction of 
metabolic activity.  This approach will serve as a system to better draw correlations between in-
vivo and in-vitro drug metabolism data.  The central hypothesis is that Cytochrome P450 
enzymes catalytic activity can be altered by protein-protein interactions occurring between 
Cytochrome P450 enzymes involved in drug metabolism, and is dependent on varying states of 
protein aggregation.  
This dissertation explains the details of the construction and characterization of a 
nanostructure device designed to control the state of aggregation of a P450 enzyme. Moreover, 
applications of immobilized P450 enzyme constructs will also be used for monitoring protein-
protein interaction and metabolite production with the use of immobilized-P450 bioreactor 
constructs.  This work provides insight into the effect on catalytic activity caused by both P450 
aggregation as well as isoform-specific protein-protein interactions and provides insight in the 
production of biosynthetically produced drug metabolites.    
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Chapter 1 - Introduction  
 
1.1.  Cytochrome P450 History 
 
The earliest evidence that suggested the occurrence of P450 catalyzed reactions was 
described early as the 1940’s, when researchers found liver homogenates capable of 
metabolizing the azo dye, 4-dimethylaminoazobenzene1. Nearly 20 years later, a protein was 
identified in liver microsomes with bound carbon monoxide after being reduced with dithionite2.  
By measuring the spectrum of the reduced form of this protein, a peak at 450 nm was observed, 
which lead the researchers to coin the term “P450”.  In 1968, it was found that a redox partner, a 
reductase, facilitated P450 mediated ω-hydroxylation of fatty acids3 eventually giving rise to the 
current model of the P450 redox complex. Eventually, human P450 enzymes were purified from 
human livers,4 though yields of these purified proteins were quite low. Finally, technological 
breakthroughs, primarily the expression of P450 enzymes in Escherichia coli, produced a 
remarkable increase in expression in bacterial cells5. This allowed scientists to generating high 
resolution crystal structures of P450 enzymes,6 necessary to fully explain structure-function 
relationships, thus further elucidating the role of these enzymes in the metabolism of xenobiotics. 
For this work, an important example is the crystal structure of CYP2C9, an enzyme which is 
utilized in much of the work presented here and is shown in Figure 1.1. 
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Figure 1.1.  Crystal structure of CYP2C9 (1R9O.pdb) (ribbon diagram). Prosthetic heme group 
(stick diagram) is shown at the center of the protein.  Figure was rendered with Pymol 
(www.pymol.com). 
 
1.2.  P450 Nomenclature 
 During early P450 enzyme based research had yet to clarify the depth and variability of 
P450 enzymes and, as such, the naming and genetic characterization was not standardized. In an 
attempt to better organize the nomenclature of P450 enzymes7,8, a universal system was 
suggested which would abbreviate all P450 enzymes, CYP enzymes. A number was chosen to 
denote the gene family, which shares approximately 40% genetic sequence identity. Next, a letter 
is used to denote the sub-family, a population of enzymes which shares approximately 65% of 
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the genetic sequence identity.  Each individual gene is labeled with a second numeral.  For an 
example of this we will use the CYP2C9 gene, which belongs to the 2 family, the C subfamily 
and finally is labeled with 9 to denote the individual gene. Mutants of CYP enzymes containing 
one or a few mutations in amino acid sequence are denoted with a * followed by a number.  For 
example the CYP2C9*3 gene, is a mutation representing a single nucleotide polymorphism 
which produces and alteration in amino acid sequence e.g. (Ile359→Leu359) for 
CYP2C9*1→CYP2C9*3.9 
 
1.3.  P450-CPR Redox Complex Structure 
P450 enzymes are primarily located in hepatic tissue and have been well characterized to 
exist as membrane associated proteins, either alone or as complexes. Generally these membrane 
bound complexes are found within hepatocytes, on the smooth endoplasmic reticulum.  The 
active redox complex consists of a single membrane-bound P450 enzyme, which is bound to the 
membrane by amino terminal transmembrane helix and a single membrane-bound Cytochrome 
P450 Reductase (CPR) enzyme5,10,11 .  These two proteins interact through a binding site on the 
surface of the P450 enzyme. Once bound, CPR can transfer electrons from nicotinamide adenine 
dinucleotide phosphate (reduced form) (NADPH) through bound flavin adenine dinucleotide 
(FAD) and flavin mononucleotide (FMN) moieties, shown in figure 1.2, to the heme iron at the 
center of the P450 enzyme12.  Generally this complex is capable of shuttling two electrons to the 
heme center, however shuttling of a second electron may also be catalyzed by a third enzyme, 
cytochrome b513 when present.  
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Figure 1.2.  Crystal structure of CPR (1AMO.pdb) (ribbon diagram). Prosthetic FMN (left) and 
FMN (right) groups (stick diagram) are shown.  Protein is presented as a dimer. Figure was 
rendered with Pymol (www.pymol.com). 
 
1.4.  P450 Catalytic Cycle 
Generally, P450 enzymes follow the catalytic reaction cycle to oxidize substrates, as 
shown in Scheme 1.2 below.  The initiation of the cycle (A) occurs when a substrate (RH) enters 
enzyme and binds to the heme-iron contained within the active site of the P450 enzyme (B)14.  
This process changes the redox potential of the P450 and produces a situation where electrons 
can be favorably transferred from NADPH through the FAD and FMN moieties contained within 
CPR14,15. The oxidation of NADPH to NADP+ is shown in Scheme 1.1. 
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Scheme 1.1.  Oxidation of NADPH to NADP+. Electrons from reaction are shuttled from 
NADPH through CPR to the heme-center of the P450 enzyme.  
 
The first electron is transferred from the NADPH-CPR complex to reduce the heme-iron 
from Fe(III) to Fe(II) (C).  The Fe(II) species is capable of binding molecular oxygen (O2), forming 
the dioxy-iron species16. Once bound, the reaction complex undergoes a second reduction of the 
heme-iron, suggesting a negatively charged superoxide complex17 (D), which is refered to as the 
ferric-superoxide complex. This facilitates the transfer of a second electron, either from CPR or 
from cytochrome b5, forming the peroxo-ferric intermediate, which is rapidly protonated to form 
the ferric-hydroperoxo species18 (E). Next, a second proton in the reaction solution migrates to 
the activated iron site, promoting the cleavage of the O-O bond in the hydroperoxo-iron, 
generating the iron-oxo species19(F). Next, the iron-oxo species is abstracts a proton from the 
substrate (G) and reacts with the substrate present in the active site, forming a hydroxylated 
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substrate (ROH)20 via (H). Finally the hydroxylated substrate (ROH) can leave the active site, at 
which point the P450 enzyme can conduct another oxidative cycle (A). 
 
 
Scheme 1.2.  Catalytic cycle of a Cytochrome P450 enzyme 
 
1.5.  Shunt Pathways of P450 Enzymes 
In addition to the productive catalytic cycle described above, P450 enzymes may also 
undergo abortive pathways highlighted in Scheme 1.2  (1,2 or 3), which restore the enzyme to its 
resting state (A)21. This protects the activity of the enzyme by preventing degradation of the 
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heme moiety, if the substrate should happen to leave the active site during the catalytic cycle. 
Autooxidation of the ferric-superoxide complex can lead to uncoupling and release of the 
superoxide species as part of the superoxide shunt pathway (1).  The cycle can also revert to its 
resting state by releasing hydrogen peroxide from the ferric-hydroperoxo species, and is referred 
to as the peroxide shunt pathway (2). Finally, the oxidase shunt pathway (3) forms after the 
activated iron-oxo species forms an excess water molecule after subsequent reduction with two 
additional electrons, and rapid protonation with two protons.  
 
1.6.  P450 Substrates and Subsequent Reactions 
Through the mapping of the human genome, it was determined that there were 
approximately 57 genes that coded for P450 enzymes.  This class of enzymes oxidizes a wide 
variety of know substrates including sterols22, fatty acids3, ecosanoids22,23, vitamins24,25 and 
xenobiotics26. Some of the more well characterized reactions catalyzed by P450 enzymes include 
hydroxylation of saturated carbon-hydrogen bonds27,28, N- and O- dealkylations 29-31, 
hydroxylations of aromatic systems28, epoxidation of olefins32, aldehyde oxidations33, 
dehydrogenation, and heteroatom oxygenation reactions34,35.  The major substrate classification 
for most human P450 enzymes can be seen in Table 1.1, below. 
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Table 1.1.  Major substrate classification of known Cytochrome P450 isoforms.  
 
Sterols Xenobiotics Fatty Acids Ecosanoids Vitamins Unknown 
1B1  
7A1  
7B1  
8B1  
11A1  
11B1  
11B2  
17A1  
19A1  
21A2 
27A1  
39A1  
46A1  
51A1  
 
1A1  
1A2  
3A5 
2A13  
2B6  
2C8  
2C9  
2C18  
2C19  
2D6  
2E1  
2F1  
3A4  
3A5 
3A7 
2J2  
4A11  
4B1  
4F12  
 
4F2  
4F3  
4F8  
5A1  
8A1 
 
2R1 
24A1 
26A1 
26B1 
26C1 
27B1 
2A7 
2S1 
2U1 
2W1 
3A43 
4A22 
4F11 
4V2 
4X1 
4Z1 
20A1 
27C1 
Table was adapted from 36-38. 
 
 
1.7.  The Role of Cytochrome P450 in the Clearance of Xenobiotics 
 
The fate of drugs in the body follows three primary means of excretion from the body, 
biliary and renal excretion and biotransformation through metabolic processes, which functions 
to facilitate renal excretion by increasing the water solubility of a compound.  The biological 
purpose of metabolism is to further facilitate excretion through either of the two formerly 
mentioned excretion routes.  Approximately 75% of the most commonly prescribed 
pharmaceutical agents are thought to undergo some sort of metabolic biotransformation to 
facilitate their excretion39. Of the compounds that are biotransformed in the body, approximately 
75% of those compounds are oxidized by P450 enzymes, accounting for the metabolism of more 
than two-thirds of commonly prescribed drugs40. As such, the relationship of xenobiotics and 
P450 metabolism are of major importance to the pharmaceutical industry.  Approximately fifteen 
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P450 enzymes have been suggested to play a role in the metabolism of xenobiotics37, and six 
(1A2, 2C9, 2C19, 2D6, 3A4 and 3A5) of these enzymes are responsible for approximately 95% 
of xenobiotics metabolized39. The breakdown of the individual contribution of each P450 
enzyme isoform is shown in Figure 1.3. 
CYP3A4/5
CYP2C9
CYP2C19
CYP2D6
CYP1A1/2
CYP2B4
CYP2E1
Other
 
 
Figure 1.3.  Contribution of each individual isoform to P450 mediated clearance. Figure 2 was 
adapted from 39. 
 
1.8.  Formation of Reactive Metabolites  
The insertion of oxygen by P450 enzymes into the chemical structure of many 
xenobiotics can often create reactive or otherwise toxic metabolites41, and represent a major 
hurdle for drug development.  The reactivity of metabolites produced by P450 enzymes can be 
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attributed to electrophilic compounds which covalently bind to either protein42 or DNA43. As a 
result, electrophilic P450 metabolites have been well characterized to generate hepatotoxicity44, 
carcinogenesis45 and increased immune hypersensitivity46. Often, cytosolic glutathione is utilized 
to react with electrophilic metabolites and serves to protect the cell from damage.  A classic 
example of this occurs with the oxidative metabolism of acetaminophen by CYP2E147.  This 
reaction generates N-acetyl-p-benzoquinone imine (NAPQI), a highly reactive metabolite which 
reacts readily with glutathione. If too much metabolite is produced, as is the case in overdose, or 
the cytosol is deficient in glutathione, the protective effect of glutathione is overwhelmed,  
NAPQI can then begin to react with proteins48 and DNA49, leading to hepatotoxicity.  
Reactive metabolites may also act as agents that act as mechanism-based inactivatiors 
towards P450 enzymes. Mechanism-based inactivation occurs when a reactive metabolite 
covalently binds to the active site of a P450 enzyme, rendering it inactive.  Generally, the 
process of covalently bonding of the reactive metabolite to a P450 enzyme carries little inherent 
toxicity50, unless the inactivated P450 is involved in a physiologically relevant pathway.  
However, if a mechanism-based inactivator is concurrently administered with a drug that is 
oxidized by the same P450, as is the case with CYP3A and some HIV protease inhibitors51, drug-
drug interaction becomes a concern in regards to toxicity.  
 
1.9.  Current In-vitro Model Systems of Cytochrome P450 Activity. 
In order to ensure prediction of the safety of a particular drug, two different in-vitro 
model systems of P450 enzymes are commonly used in early drug development scenarios. One 
of the more commonly used models of P450 metabolism consists of homogenized liver tissues, 
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where the smooth endoplasmic reticulum containing active P450 redox complex is purified by 
ultracentrifugation to form human liver microsomes.  Human liver microsomes are valuable tools 
to better predict how a drug may be metabolized within the body. These microsomes generally 
contain all of the enzymes present in the liver and as such, they provide a reasonable in-vitro 
model to predict drug metabolism in early in drug development.  However, because the entire 
compliment of hepatic P450s is expressed, human liver microsomes offer little insight into which 
enzymes are primarily involved in metabolism of a drug, which is essential to mitigate inhibition 
of P450 enzymes.  
Alternatively, recombinant expressed P450 enzymes developed in the early 1990’s by 
Barnes and colleagues5 are often used to elucidate the role of single P450 isoforms in regards to 
the metabolism of a particular drug. In order to properly mimic the natural environment of the 
P450 enzyme and facilitate their inherent catalytic activity, they are typically mixed with charged 
phospholipids52, which will generate a simulated microsomal structure and are thought to 
promote the interaction of P450 enzymes with redox partners such as CPR, thereby encouraging 
catalytic activity53. Once formed, these reconstituted “artificial microsomal” incubations are 
particularly useful in studies of P450-substrate interactions.  Additionally, by having a system 
that can be tailored with variable amounts and types of enzymes present, these systems are useful 
in studying protein-protein interactions between P450 and CPR enzymes54, as well as P450-P450 
interactions between different isoforms55. 
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1.10.  Drug-drug Interactions 
 Solved crystal structures of P450 enzymes have shown that the active site of these 
enzymes is often quite large6, and P450 enzymes have been characterized to interact with and 
metabolize a wide variety of compounds56. As a result these enzymes are a major site for drug-
drug interactions within the body.  Knowledge of drug-drug interaction is continuously sought by 
the pharmaceutical industry and presents a major bottleneck for the further development of 
compounds.  Interactions can be primarily generalized into two different categories including 
activation or inhibition of a P450 enzyme, and both have implications in clinical outcomes.   
Most commonly, drug-drug interactions arise when the metabolism of a drug is inhibited 
by the simultaneous administration of a second drug, through, for example, competitive 
inhibition. This occurs when an inhibitor compound enters the active site, either reversibly or 
irreversibly, and prevents the access of a substrate molecule. By preventing access of substrate 
molecules, a situation is created where the metabolism of a drug is slowed significantly, altering 
metabolism kinetics. Clinically, this can lead to drug toxicity by leading to high levels of drug 
within the body.   
Conversely, the large active site of P450 enzymes can often support two to three 
substrates, simultaneously in the active site in the enzyme.  This scenario can present a situation 
where a substrate spends more time in a productive binding orientation in the effective enzyme 
of interest, creating a situation where the catalytic activity of the enzyme is dramatically 
increased57. Clinically, this can often equate to sub-therapeutic concentrations of drugs present 
within the body, and is a situation that should be avoided to increase the efficacy of a drug.  
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1.11.  Kinetic Evaluation of P450 Enzymes 
 To measure enzyme kinetics as well as identify potential drug-drug interactions in 
reconstituted incubations using recombinant P450 enzymes, mathematical models have been 
developed to provide further insight into these processes.  The simplest model for kinetic 
evaluation of a P450 enzyme-substrate interaction is typically based on a Michaelis-Menten 
model.  This model, in a simple form is shown in Equation 1.  
S + E SE E + P
k1
K-1
k2
k
(1)
 
In this model, S is the substrate, E the enzyme, and P the product (metabolite) of the 
reaction between the substrate (S) and the enzyme (E). The reaction rates can be characterized as 
k1, or the rate at which the substrate bound enzyme complex forms.  The rate constant k-1 is a 
measurement of the rate at which the substrate bound enzyme complex dissociates into substrate 
and enzyme.  Finally, k2, is the reaction constant for the formation of the product, and is 
frequently the rate limiting step. 
Through derivation of several equations regarding enzymatic rate as well as substrate and 
enzyme concentration, the Michaelis-Menten equation can be derived, shown in Equation 2. This 
equation allows one to determine the reaction velocity (V0) at any point at any substrate 
concentration ([S]), given that you can obtain so information regarding the kinetics and binding 
of substrates.  
v0 =
Vmax [S]
Km + [S]
(2)
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Typically, Michaelis-Menten like kinetics is a saturable process, meaning that as 
substrate concentration increases, the reaction will reach a maximum velocity (Vmax).  The Vmax 
term, shown in Equation 3, is derived from the rate limiting step, which is usually k2 (commonly 
refered to as the turnover rate) multiplied by the total enzyme concentration. 
V = k  [E]max 2 tot (3)  
Finally, the Km of the system, commonly referred to the Michaelis constant, is 
determined by the Equation 4 and is derived from the model of enzyme kinetics (Equation 1). 
Km=
k-1+k2
k1
(4)
 
The Km is often related to the affinity of the enzyme for the substrate; however particular 
cases exist where this is not always the case. Conveniently, when generating Michaelis-Menten 
plots, the Km value is the substrate concentration that generates approximately  ½ Vmax value.  To 
generate Michaelis-Menten like plots, the velocity of the reaction is measured, which in the case 
of P450 enzymes is typically determined by the concentration product formed, divided by time, 
divided by the concentration of P450 present in the incubation. By plotting the velocity of the 
reaction against the concentration of substrate, a sigmoidal curve is often generated, indicating 
that enzyme kinetics is a saturable process.  An example of this type of curve can be seen in 
Figure 1.4 below. 
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Figure 1.4.  Generic plot representing Michaelis-Menten kinetics commonly observed in P450 
biotransformation. 
 
Essential to these Michaelis-Menten type studies using P450 enzymes is monitoring 
drug-drug interactions and their effect on Km and Vmax, and has also been observed in studies 
characterizing P450-P450 interaction. In cases of competitive inhibition, an inhibitor molecule 
will competitively bind to the active site, inhibiting substrate turnover, typically resulting in a 
decrease in Vmax and an increase in Km.  The result of this can be observed in Figure 1.5, where a 
theoretical inhibitor decreases the catalytic turnover of a substrate.    
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Figure 1.5.  Generic plot representing inhibition in Michaelis-Menten kinetics (grey dashed 
line). 
Michaelis-Menten like kinetics is commonly used as the simplest model to characterize 
enzyme kinetics, and often for studies involving drug-drug interactions in P450 enzymes, they 
are sufficient.  However, kinetic modeling of enzymatic reactions is often extremely complex, 
and thus different models have been developed, accordingly, to deal with these issues.   
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1.12.  Aggregation in In-vitro P450 Incubations 
Mammalian P450 enzymes exist as membrane-associated proteins, and as a result have 
several hydrophobic domains within their tertiary structure to interact with the endoplasmic 
reticulum10. Normally when a membrane is present, as is the case with intact hepatocytes, the 
P450 enzymes associate (bind) with the membrane and exist in a monomeric state. In contrast, 
when these enzymes are expressed and purified from Escherichia coli for use in biochemical 
experiments, the membrane components from these bacterial cells are washed away with a 
variety of detergents. The resulting P450 exists in solution with its hydrophobic, transmembrane 
domain exposed to water, and, as a result aggregation of P450 monomers through these 
hydrophobic domains forms large aggregates of P450 enzymes. Consequently, it becomes nearly 
impossible to distinguish deliberate protein-protein interactions thought to be involved in 
catalytic processes, from those interactions that occur as a result of exposed hydrophobic 
domains, which may contribute to random protein aggregation. 
 
1.13.  Flexibility in P450 Enzymes 
 In addition to having a very large active site, several P450 enzymes exhibit extensive 
flexibility within their active site.  Typically, substrates with large active sites, CYP2C9 and 
CYP3A4 being classic examples, demonstrate high levels of active site flexibility58.  As a result, 
flexibility in the active site can modulate activity of a P450 towards a given substrate.  
Malleability of the active site may have effects on the catalytic activity of a P450 enzyme 
depending on both the substrate structure and absolute flexibility within the active site. 
Moreover, it is unclear to this point how aggregation of P450 enzymes may be affecting enzyme 
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flexibility, which may present a reasonable mechanism to explain altered catalytic activites as a 
result of P450 aggregation.  
 
1.14.  Techniques to Reduce P450 Aggregation In-vitro 
The role protein aggregation may play with purified P450 enzymes has been well 
characterized and often it has been shown that it can play a role in the catalytic activity of the 
P450 enzymes59. As a result, several different techniques have been explored to reduce or control 
the state of aggregation of recombinant P450 enzymes. Techniques include mutation of the 
enzyme structure such as mutation of key residues or truncation of the N-terminal domain, 
changes to the components of the enzyme incubation mixture including altering salt and 
detergent concentrations, use of a helical protein belt designed to make nanoscale lipid bilayer 
structures referred to in the literature as a Nanodiscs, and finally immobilization of the enzyme to 
a solid substrate.  
  
1.14.1.  Enzyme Mutation 
With the development of recombinant DNA technology, production of P450 mutants has 
become an increasingly feasible technique to elucidate structural elements involved in P450 
aggregation.  Two main strategies are used to reduce aggregation of P450s: through enzyme 
mutation including 1) truncation of the N-terminus and 2) point mutations of amino acids 
thought to be involved in P450 protein-protein interactions. Truncation of the N-terminus has 
been probed in several different P450 isoforms including CYP2B4, CYP2E160,61 and CYP1A262.  
These studies concluded that the N-terminus played a key role in the formation of P450 
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aggregates, through hydrophobic domains contained within the N-terminal domain of P450 
enzymes.  It was shown that removal of the N-terminal domain would tend to drive the P450 into 
pentameric or hexameric structures, preventing formation of large aggregates.  None of the 
truncated P450 enzymes were found to form monomers in the absence of detergent60,61, and 
truncated CYP1A2 was found to form aggregates even in the presence of several detergents62.  
Moreover, many of the N-terminal truncated P450 enzymes show decreased activity over the 
wild type enzyme, making them unsuitable for probing changes in catalytic activity of a P450 
enzyme as a function of aggregation state.  
In addition to truncation of the N-terminal sequence of a P450 enzyme, point mutations 
of amino acid residues of CYP2C5 has also been shown to reduce the aggregation of P450 
enzymes63. Interestingly, many of these mutations provided the enzyme the ability to exist in 
monomeric form in the absence of detergent.  However, these mutations also produced a variety 
of catalytic activities depending on the location of a mutation.  As a result, this approach makes 
it difficult to determine whether the resulting decrease (or increase) in catalytic activity is a result 
of a change in aggregation state or in the tertiary structure of the enzyme.     
  
1.14.2.  Detergent 
As was previously discussed, detergents such sodium cholate were often used with 
truncated P450 enzymes to generate monomeric structures64.  Furthermore, the use of Emulgen 
91365 or n-octylglucoside66 on full length P450 enzymes has also been explored.  One study in 
particular took an in depth look at the catalytic activity of CYP1A2 in incubations containing 
Emulgen 91365.  It was discovered that at high concentrations of Emulgen 913 (8 g/L), P450 
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enzymes would form monomeric structures and from a kinetic standpoint, these monomeric 
forms of P450 enzymes were less active than their pentameric counterparts.  Interestingly, it was 
also discovered that monomeric CYP1A2 has increased catalytic activity over aggregates of 
CYP1A2 in incubations containing no Emulgen 913. However, due to the high concentration of 
detergent involved in these studies, it is difficult to determine whether the decrease in catalytic 
activity is a true result of the monomeric state of the enzyme, or if these high concentrations of 
detergent hinder interaction between P450 and reductase, thereby reducing apparent activity.  
 
 1.14.3.  Nanodisc® 
The interaction of enzymes and receptors with lipid bilayer structures is essential to 
retaining activity and function of a membrane bound protein. Recently, techniques have been 
developed to study membrane bound proteins such as G-protein coupled receptors67 and P450 
enzymes68 in discs of phospholipids bilayers of uniform shape and size.  By forming a bilayer 
structure of specific dimensions, researchers can better produce a homogenous membrane 
environment, eliminating variables associated to membrane formation. Furthermore, in the case 
of P450 enzymes, these Nanodisc® structures have been used to reduce the aggregation of a P450 
enzyme by providing a discoidal piece of membrane that is only capable of binding a single P450 
enzyme.  The presence of monomeric P450 enzymes has confirmed by atomic force microscopy 
(AFM) imaging69. 
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1.14.4.  Immobilization of P450 Enzymes 
A final approach to controlling the aggregation state of a P450 enzyme is to covalently 
immobilize these enzymes to a surface.  Several groups have immobilized P450 enzymes to a 
variety of substrates including gold70,71, sol-gel films72, glassy carbon73and pyrolytic graphite.74  
A large majority of the research concerning immobilized P450 enzymes has taken advantage of 
the redox capabilities of this enzyme and coupled it to electroactive materials to elucidate the 
mechanism of electron transport75 and substrate binding71.  A key study conducted in our lab 
found that the presence of two CYP2C9 substrates, flurbiprofen and dapsone, capable of 
simultaneous binding to the heme-center of the P450 enzyme enabled the protein to remain 
metabolically active and utilize the natural cofactors (NADPH) and coenzymes (CPR)70.  Upon 
inspection of the enzyme immobilized gold surface with AFM, it was demonstrated that this 
surface had a propensity to keep P450 enzymes in a monomeric state.  As a result, this platform 
may be advantageous for both monitoring metabolic activity of monomeric CYP2C9 as well as 
probing for protein-protein interactions with other P450 enzymes.  By utilizing this method, the 
use of mutations can be avoided since this may change the tertiary structure of the enzyme as 
well as eliminate the use of detergents within an incubation which may prevent interactions 
between P450 enzymes as well as interactions with reductase. Furthermore, by developing a 
construct based on gold thin films, we have provided additional capabilities, such as using the 
construct to examine interactions in real time, using techniques such as surface plasmon 
resonance (SPR). 
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1.15.  Protein-Protein Interactions Between P450 Isoforms 
Given the presence of several different P450 enzymes in the endoplasmic reticulum of 
hepatocytes, protein-protein interactions between different P450 enzymes may be playing a role 
in the metabolism of xenobiotic compounds.  Further supporting the idea of protein-protein 
interactions between different P450 enzymes is the low concentration of cytochrome P450 
reductase present within hepatocyte cells.  It has been estimated that concentrations of P450 to 
CPR in hepatocyte cells is approximately 20:176, suggesting that CPR is a limiting factor in P450 
reactions which requires a 1:1 complex of P450 to CPR for optimal function77.  Several groups 
have characterized potential protein-protein interactions between P450 enzymes resulting in 
modulation of catalytic activity78-82. However, these experiments utilize reconstituted systems to 
conduct their incubation studies, which may be difficult to use in elucidating which protein-
protein interactions are a result of a specific protein-protein interaction from those interactions of 
a non-specific, aggregative nature.  
 
1.16.  Self-assembled Monolayers 
 Recent scientific discoveries in the field of materials science, particularly the formation 
of biomimetic surfaces, have found several applications in the field of biomedical sciences 
including use in cell culture substrates83, biosensors84 and bioelectronics71.  This research has 
been largely supported by the formation of well ordered films of monomolecular thickness, 
which owe their origins to work in biology, on a variety of different surfaces, commonly refered 
to as a self-assembled monolayer (SAM). SAMs can be formed by a variety of different ways, 
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but for the context presented here, we will describe the formation of two different types, thiol-
gold SAMs as well as silane-silicon dioxide SAMs, both prepared from solution.  
 
 1.16.1.  Thiol-gold Based SAMs 
Certain metallic surfaces, when exposed to organothiol85 or organoselenol86 compounds 
are known to form ordered SAM structures. These organothiol (organoselenol) films on gold85 
have been well characterized in the literature, however, thiol-SAMs have also been characterized 
to form on copper87, silver88 and palladium89, which only serve to increase their applications in 
bioelectronics and biomimetic surface fabrication. These SAMs are typically formed by 
immersing a thin film of metal, typically gold, in an ethanolic solution of thiol (selenol) resulting 
in the spontaneous formation the desired self-assembled monolayer.  A schematic for this 
process is shown in Scheme 1.3. 
SH
SH
SH
OH
O
SH
AuAuAuAu
AuAu
S S
AuAu
S S
OH
O
+
 
Scheme 1.3.  Formation of a thiol-based SAM on a gold film. 
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The formation of self-assembled monolayers of organothiols on gold is a random and 
spontaneous process.  As a result SAMs of mixed thiol composition often form unevenly 
distributed nano-sized domains of thiol-based structures within a particular thin film90.  This can 
lead to large areas of the SAM structure to form heterogeneously mixed monolayers, often 
complicating the architecture of the biomimetic surface. As a result it would be ideal to generate 
nanostructure devices and biomimetic surfaces which can control uncertainty in formation of 
SAMs, and provide researchers with tools capable of precise control of interactions between 
engineered materials and biological entities. 
 
1.16.2.  Silane-silicon Dioxide based SAMs 
SAMs can also be prepared on oxide-containing surfaces such as silicon dioxide91, when 
treated solutions containing silanes92. In addition to the formation of SAM structures on silicon 
dioxide, silane based SAMs have also been formed on various other oxide surfaces such as 
aluminum oxide93, germanium oxide94 and indium tin oxide95.  Typically, silanes in silane-based 
SAMs form a covalent bond between the silicon atom and a surface oxygen and bond as shown 
in Scheme 1.4.  Interestingly, silane-based SAMs are typically more robust then gold thiol 
SAMs, however they are much more difficult to produce, largely because of their dependence on 
there being the correct amount of water being present for proper polymerization across the 
sample interface. Silane-based SAMs formed in deficient concentrations of water often form 
sparsely packed monolayer structures.  In contrast, SAMs formed in high concentrations of water 
tend to form self-polymerized SAMs, which affect the structure of the SAM and cause the film 
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to lose its true monolayer form.  Research has indicated that the proper concentration of water in 
a solution used for formation of silane-based SAMs is approximately 0.15mg/mL96.  
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Scheme 1.4.  Formation of a silane-based SAM on a silicon dioxide wafer. . 
 
1.17.  Characterization of Gold-immobilized Constructs 
Characterization of immobilized proteins to a variety of surfaces, to demonstrate 
bonding, can be accomplished by a wide array of techniques. For the purposes of this project, 
four different characterization techniques, three which were applied, will be discussed here. 
These are contact angle goniometry, x-ray photoelectron spectroscopy (XPS), surface plasmon 
resonance (SPR) and self-assembled monolayer desorption ionization mass spectrometry 
(SAMDI-MS).   
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1.17.1.  Contact Angle Goniometry 
One of the simplest means to characterize a SAM is through contact angle goniometry, a 
technique to measure surface wettability (tensiometry)97. Furthermore, with the development and 
formation of a variety of SAMs on a wide range of surfaces98,99, contact angle goniometry has 
become an indispensable technique to characterize surface energetics. To obtain static contact 
angle measurements, a drop of deionized water is placed on to a surface of interest, allowing for 
it to rest for a period of time to insure a thermodynamic equilibrium has been formed between 
the three separate phases: solid, liquid and gas. In its most simple form, static contact angles are 
determined by taking a measurement of the angle (θY), formed by a liquid-gas interface when in 
contact with a solid surface.  A diagram of this phenomenon and how is (θY) is obtained is shown 
below in Figure 1.6.  More complex measurements can be made using contact angle goniometry, 
such as advancing and receding contact angles which give greater insight to the free energy 
associated to the system97.  
 
Figure 1.6.  Diagram outlining the obtainment of (θY) by using contact angle goniometry. 
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Measurement of static contact angles for immobilized constructs is a quick and robust 
way to characterize changes in surface chemistry. Measurement of static contact angles can be 
used in characterization of the formation of SAMs on gold100 as well as silicon dioxide101. 
Moreover, contact angle goniometry can also be used to monitor changes in surface chemistry  
which are a result of a chemical reaction occurring at an interface100, particularly reactions 
involving the formation of N-hydroxysulfosuccininmide (NHS) esters.  Finally, this technique 
can also be used to demonstrate changes in θY as proteins are adsorbed or bonded to a surface102. 
 
1.17.2.  X-ray Photoelectron Spectroscopy 
Elemental analysis of a SAM or protein-immobilized-SAM surfaces can be accomplished 
by irradiating a sample with an x-ray beam and measuring the subsequent energy of electrons 
released from the sample103.  This technique is referred to as x-ray photoelectron spectroscopy 
(XPS) or electron spectroscopy for chemical analysis (ESCA). The general principle of this 
technique is demonstrated in Figure 1.7.  XPS allows for the measurement of the electron 
energies of ejected electrons from both core and valence levels, providing an advantage over 
ultraviolet photoelectron spectroscopy (UPS), which can only characterize electrons from 
valence levels104. The capability to characterize core electrons has led to the utilization of this 
technique to determine discrete energies of core electrons corresponding to individual elements, 
thus providing simple elemental analysis of surfaces or surface bound materials within 
approximately 10 nm of the sample interface.  Furthermore this technique can be used to 
measure energy of ejected electrons as a function of localized environment, providing insight 
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into types of bonds.  Here, there is particular interest for carbon and nitrogen104, at the surface as 
these elements are part of the SAM, protein or both.   
 
Figure 1.7.  Diagram of X-ray Photoelectron Spectroscopy 
 
1.17.3.  Surface Plasmon Resonance 
Initially, surface plasmon resonance sensors were used in the detection of gases105.  The 
discovery and use of surface plasmon resonance (SPR) to characterize organic monolayers on 
thin films of silver occurred around the mid 1970’s106.  Coupling in formation with respect to 
SAM comprised of, for example alkanethiols based-films of monomolecular thickness on gold85 
increased the diversity of chemistry which could be applied to SPR substrates.  Since that time, 
an explosion of research107 in the field of SPR based sensors has occurred. This class of sensors 
has found further use for the detection of gases108,109, chemicals, including ions110 and small 
molecules111, as well as detection of biomolecules such as proteins112, DNA113 or RNA114. 
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To conduct SPR experiments, an SPR goniometer must be fabricated, for which the basic 
diagram of this set up is shown in Figure 1.8. In its most simple terms, SPR forms an extremely 
sensitive mass sensor. To accomplish this, a thin piece of glass is interfaced with a prism (bottom 
side) and a flow cell (top side).  P-polarized light is transmitted through the prism where it 
interacts with the glass, which carries a higher refractive index than the dielectric media present 
in the flow cell (water).  The difference in refractive index at the interface of the glass and water, 
induces total internal reflectance (TIR), resulting in all of the light being reflected from the 
interface.  
SPR substrates are coated with a conducting material, typically gold or silver, of a very 
specific thickness (50 nm)115.  As the p-polarized light strikes the gold coated glass slide, it 
induces the formation of a surface plasmon wave which propagates across the film.  In addition 
to the formation of a plasmon wave, the reflectance spectra of a gold-coated glass slide has a 
characteristic trough or intensity minimum of the light reflected from the interface, for which the 
absolute minimum is referred to as the SPR angle (θSPR).  The plasmon wave oscillates into the 
dielectric medium (water) and is extremely sensitive to changes in refractive index at the 
interface of the gold film and water.  In the case of biosensors, proteins will covalently bond or 
adsorb to the surface and will modify the localized refractive index causing an effect in the 
propagation of the plasmon wave.  As the plasmon wave is modulated by changes in localized 
refractive index, it generates a shift in θSPR, which is measured as a change in response by the 
SPR spectrometer. 
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Figure 1.8.  Diagram of Surface Plasmon Resonance Spectroscopy 
 
 SPR based biosensors have found application in several different areas of pharmaceutical 
sciences.  In P450 research, SPR spectroscopy has been used to characterize binding of azoles to 
CYP3A4.  Other applications of SPR involving small molecule binding to pharmacologically 
active targets including p38116, a protein involved in pro-inflammatory cascades.  SPR surfaces 
can be modified to support membrane bound receptors, which are common pharmacological 
targets.  The use of a biomimetic surface will support membrane associated receptors, such as g-
protein coupled receptors117, which are common pharmacological targets.  This may represent a 
simple approach to characterize small molecules binding to receptors. Finally, SPR has found 
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application in large molecule drugs as well, having been used in observing interactions of 
therapeutic antibodies with biological targets118.   
 1.17.4.  Atomic Force Microscopy 
Atomic force microscopy (AFM) is a type of scanning probe microscopy technique 
developed in the mid 1980’s119 to characterize surface topography of a variety of materials in a 
minimally invasive manner.  Prior to this, imaging techniques, particularly of soft materials 
(protein, DNA) was conducted with transmission electron microscopy or scanning electron 
microscopy.  In both of these cases, samples must be kept in a vacuum chamber during imaging, 
as an electron beam is directed at the target, and may be denatured under high vacuum 
conditions. Additionally, optical microscopy techniques, under ideal conditions (oil immersion 
lens) have a resolution of approximately 200 nm, far below the resolution needed to image a 
single P450 enzyme with a 6nm diameter.  In contrast, AFM provides a resolution of around <1 
nm, making it suitable to characterize proteins immobilized to a surface. 
 AFM can provide topographical images at the atomic-level using a specialized probe 
called an AFM tip. Normally, the tip is driven at resonance (z-direction) causing it to oscillate at 
a specific frequency.  As the tip oscillates, it is moved along the surface (x-y direction) where the 
oscillations in the cantilever will be affected by changes in the topology of the surface.  The 
oscillations of the tip are monitored with a laser, which is reflected onto a position detector, a 
photodiode array.  As the tip comes into contact with the sample, the deflection of the laser off of 
the tip generates a topographical image.  A schematic drawing of this is shown in Figure 1.9.    
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Figure 1.9.  Diagram of the key parts of an atomic force microscopy (AFM) experiment 
 
 Since its invention in the mid 1980’s, an explosion of atomic force microscopy research 
centered on the life sciences has occurred.   AFM has been suggested as a complementary 
technique to x-ray diffraction in elucidation of protein structure120. Furthermore, because AFM 
can be used under physiological conditions, this technique has been useful in characterization of 
cell surface proteins using “wet” AFM121 conducted in cell media.   Additionally, protein-protein 
interaction experiments have been devised where an AFM tip is functionalized with a protein and 
is used to image a cellular surface.  The tip-bound proteins will interact with cell membrane 
receptors, locating and quantifying them121,122.  This technique is not only useful for developing 
molecular recognition images, but may also provide some insight into the biophysics of protein-
protein interactions.  With respect to P450 enzymes, AFM has been used to characterize the 
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formation of complexes of P450 enzymes with other enzymes123,124, as well as monitor 
interaction of P450 with membrane structures125. 
 
 1.17.5.  Self-Assembled Monolayer Desorption Ionization-Mass Spectrometry 
Analysis of proteins immobilized to self-assembled monolayers with mass spectrometry has led 
to the development of a technique126 referred to as self-assembled monolayer desorption 
ionization-mass spectrometry (SAMDI-MS).  This technique has several applications including 
monitoring chemical reactions that occur at interfaces127 as well as probing protein-SAMs and 
protein-protein interactions128. Additionally the methods described here have also been coupled 
to SPR based sensing technologies to complement real-time monitoring of protein-protein 
interactions with the ability to identify adsorbed molecules129.  
 As SAMDI-MS was developed, it was still unclear how mass spectra from SAM 
structures were generated. Eventually, it was concluded that the mechanism surrounding the 
desorption of SAMs from a gold surface during SAMDI-MS was due to solubilization of the 
SAM molecules into the MALDI-MS matrix and solvent after application to the SAM130. 
Literature reports suggest that the Au-S bond made during the formation of SAMs, is regularly 
broken in solution.  Free thiols from solution can readily exchange with thiols on the surface and 
vice versa131.  As a result, in SAMDI-MS experiments, when thiol containing SAMs are treated 
with the SAMDI-MS matrix (2′,4′,6′-trihydroxyacetophenone in methanol), they become 
dislodged from the SAM and are dissolved into the matrix solution.  Upon methanol evaporation, 
the resulting matrix crystals contain SAM components, co-crystallized within that matrix. The 
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matrix is then exposed to laser light, desorbing matrix components, and mass spectra are 
acquired. A schematic drawing for this process is shown in Figure 1.10.   
 
Figure 1.10.  Diagram of SAM dissolution and crystallization in SAMDI matrix. 
 
1.18.  Project Aims 
 Prediction of in-vivo drug metabolism using reconstituted incubations of P450 enzymes 
in-vitro is a useful technique to establish metabolic parameters of a drug early in development. 
Generally these reconstituted incubations consist of P450, reductase, phospholipids and NADPH 
to generate a simulated microsome. However, reconstituted incubations often promote the 
aggregation of P450 enzymes, which can often exhibit allosteric effects on the enzyme altering 
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its catalytic activity.  Accordingly, the need for improved in-vitro models which can control the 
state of aggregation of a P450 enzyme must be developed.  
 P450 enzymes in-vivo are typically expressed along with the entire complement of P450 
isoforms.  The presence of sub-saturating concentrations of reductase present on the endoplasmic 
reticulum suggest that protein-protein interactions may be occurring within hepatocytes to affect 
the metabolism of a particular drug.  To elucidate protein-protein interactions between P450 
enzymes, mixed enzyme incubations containing two or more P450 enzymes are designed, and 
the resulting catalytic activity of the enzyme is measured. These mixed enzyme systems are also 
prone to aggregation as mentioned above, making it difficult to elucidate whether changes in 
catalytic activity are a result of a specific protein-protein interaction or a result of random 
aggregation.  As a result, it would be extremely useful to develop models to which we can study 
interaction of monomeric P450 enzymes with one another. 
 The long term goals of this project are to develop in-vitro models designed to 
unequivocally control the aggregation state of a P450 enzyme.   The use of these methods will 
assist in addressing the catalytic activity of monomeric P450 enzymes using an immobilized 
enzyme construct.  These models will also provide a means to measure on-off rate kinetics to 
elucidate protein-protein interactions between P450 enzymes. In turn, these models may provide 
a better prediction of drug metabolism in-vivo, saving lost time and resources on compounds 
which have unacceptable metabolic characteristics.   Moreover, these models, which contain 
active, immobilized P450 enzymes, can also be used for metabolite generation in bioreactor 
applications, providing a means to biosynthetically generate metabolites for toxicity studies. 
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Project Aims 
1.) Employ a nanostructure device designed to selectively bind enzymes to a surface to 
reduce the level of aggregation in reconstituted P450 incubations. 
2.) Develop an immobilized P450 construct for applications probing protein-protein 
interactions as well as metabolite generation. 
  
  This dissertation will discuss the development of a nanostructure device designed to 
reduce the aggregation of P450 enzymes. The fabrication of this device and the methods used to 
characterize the device will be thoroughly discussed.  Specifically we will use SPR to 
characterize real-time CYP2C9 adsorption to a variety of model self-assembled monolayers.  We 
will use XPS to describe the adsorption of CYP2C9 to model self-assembled monolayers as well 
as use this technique to monitor changes in surface chemistry during the fabrication of the 
device. Finally, we will demonstrate that the P450 remains active on a surface containing ~100 
nm “nano-beakers” demonstrating that proteins bound to the surface demonstrate activity in the 
presence of natural cofactors and coenzymes. 
 In addition to the nanostructure device, I will also describe the application of a method 
using SAMs of 3:1 octanethiol:mercaptoundecanoic acid to an SPR experiment.  This 
experiment will directly measure on-off kinetic rates for immobilized CYP2C9 and solution 
CYP2D6, thus providing insight into protein-protein interactions between P450 enzymes.  I will 
discuss how the immobilized CYP2C9 construct was used in an incubation containing increasing 
concentrations of CYP2D6, and this incubation exhibits no effect on the activity of immobilized 
CYP2C9.  This information is in contrast to data presented in solution, further highlighting 
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differences between solution and immobilized P450 incubations.  These differences may provide 
insight into the effect of protein aggregation and protein-protein interaction between P450 
enzymes.  Finally, I will use immobilized CYP2C9 to generate two approaches; a plug-flow and 
a batch bioreactor, capable of generating metabolites for use in toxicity studies. Ultimately, these 
approaches will assist in generating new in-vitro models which may provide better predictions of 
in-vivo drug metabolism and toxicity. 
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Chapter 2 
 
Applications of Immobilized CYP2C9 
for Use in Bioreactor Constructs to 
Biosynthetically Generate Drug 
Metabolites 
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2.1.  Introduction 
Cytochrome P450 (P450) enzymes have been shown to play a major role in the 
metabolism of pharmaceutical compounds132.  In order to bring a new drug to market, or to 
determine the continued safety of currently marketed pharmaceuticals, drugs are screened with 
human enzymes for metabolism. When metabolites are formed, it is necessary to the assess 
toxicity of each particular metabolite133.  In many cases, pharmaceutical compounds have been 
found to be metabolized by P450 enzymes and generate toxic reactive intermediates and/or 
metabolites134.  Deleterious effects of these species include systemic and hepatotoxicity135,136, 
mechanism based inactivation of P450 enzymes137, or increased immune hypersensitivity.46  
Therefore, it is extremely important for pharmaceutical companies identify compounds that are 
metabolized to toxic or reactive species early in the drug development process to mitigate losses 
of research dollars on compounds that are unsafe, and thus could not be brought to market.  To 
accomplish this, researchers need to synthesize large quantities of metabolites to conduct toxicity 
testing. 
Traditionally, metabolites and other compounds of interest to researchers were 
structurally elucidated using mass spectrometry (MS) and nuclear magnetic resonance (NMR) 
spectroscopy.  Once compounds were characterized, synthetic schemes were generated and the 
compound then synthesized using traditional organic chemistry techniques. However, this 
process is often extremely time-consuming, resulting in increased labor costs and delaying the 
development process.  Often the synthetic process required to produce the compounds of interest 
often requires harsh conditions and dangerous reagents, further emphasizing the need for safe 
and efficient production of compounds of interest.     
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 Reactions of P450 enzymes are well known for producing compounds of very specific 
stereochemistry138. This increases the difficulty of synthesizing metabolites, as reactions 
typically generate racemates. While racemic mixtures can be separated, this can be difficult, 
reduces yields, and, in turn, increases the time and expense of preparing desired metabolites.  
Furthermore, P450 enzymes have been characterized as extremely powerful oxidizing 
agents and have been shown to carry out a variety of reaction types, including N- and O- 
dealkylations, hydroxylations of aromatic systems as well as saturated carbon-hydrogen bonds, 
and heteroatom oxygenation reactions139.  As a result, P450 enzymes have been shown to play a 
key role in the synthesis of several different compounds140,141, many of which would be very 
difficult to prepare with traditional synthetic organic chemistry. 
Traditionally, bioreactors are devices which are designed to carry out some sort of 
bioprocess142.  These bioprocesses can be conducted by either by living organisms, such as 
cultured cells143,144 and bacteria145, or can consist components with biochemical activity such as 
enzymes146. In the pharmaceutical industry, bioreactors are commonly utilized to generate 
products of interest, such as small molecules147 and proteins148.  
The physical design of bioreactors traditionally fall into two general types of bioreactors 
commonly used in industrial applications. These include, batch and continuous flow bioreactors.  
Batch bioreactors have no flow of nutrients in and out of the bioreactor.  They are generally 
inexpensive to make. However a major drawback of this approach is the build up of waste 
products, which may decrease the overall efficiency of the bioreactor.  
In contrast, continuous flow bioreactors have a flow in and out of the reactor and have a 
variety of configurations possible, including bioreactors that are made of a simple tube or 
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channel to which reagents are supplied and are commonly referred to as plug-flow bioreactors.  
Generally these types of devices are highlighted by a tube-shaped structure which contains a 
catalyst on the walls of the tube and an inlet flow of reactant.   The constant flow of media and/or 
chemicals into and out of the plug-flow bioreactors is advantageous in that these types of 
bioreactors have a continuous exchange of fluid flowing throughout the bioreactor. However, 
their design is generally more expensive to build when compared to batch bioreactors.  The 
mixing of the reactant, particularly in the axial direction, in plug-flow bioreactors is usually 
significantly lower than in continuously stirred bioreactors.  Finally, temperature in plug flow 
bioreactors is difficult to control, resulting in the formation of undesired temperature gradients. 
Recent technological advantages including the production of recombinant P450 
enzymes149 has lead to the efficient production of enzyme at extremely high concentrations, in-
turn reinforcing their potential use as synthetic tools in bioreactor applications.  Current 
strategies for bioreactor-based metabolite generation include the use of bacterial150, insect151,152  
and hepatocyte153 cell-based systems. Other strategies include the coupling of human liver 
microsome (HLM) based systems to HPLC instrumentation154,155 in a plug-flow set up. In the 
case of the latter system, these constructs provide a tool for structural determination of 
metabolites from pharmaceutical compounds, and are not intended for the generation of large 
quantities of metabolite necessary for toxicity testing or other research and development 
activities. Moreover, bioreactors containing whole cells require constant maintenance of the cell 
media, including removal of waste products and proper regulation of temperature, often requiring 
extensive and costly bioreactor setups. 
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Here we present two independent bioreactor designs one a plug-flow bioreactor, in which 
we chemically bond Cytochrome P450 2C9 (CYP2C9) to a PMMA surface and, the second a 
batch bioreactor where we utilize electrochemistry to oxidize substrates at an electrode bearing 
an immobilized P450 (CYP2C9).  In both instances, amine directed coupling of recombinant 
CYP2C9 to a self-assembled monolayer (SAM) on gold or PMMA, is achieved conducting the 
bonding in the presence of two substrates, flurbiprofen and dapsone, which are hypothesized to 
stabilize the active site during the attachment (bonding) of the CYP2C970. Furthermore, we have 
optimized several other factors including different attachment schemes, CYP2C9 attachment 
concentration and CYP2C9 attachment time on proof of concept bioreactor “chips” to increase 
metabolite output. Finally, we have fabricated PMMA based bioreactors using a plug-flow like 
channel and demonstrated its ability to generate metabolites of interest from a probe substrate, 
diclofenac.   
 
2.2.  Materials and Methods 
 
2.2.1.  General 
Unless otherwise noted, phosphate buffer (KPi) was made by mixing 40mM solutions of 
both dibasic and monobasic potassium phosphate such that the resulting solution of mixed 
components had a measured pH of 7.4. Mixtures of N-(3-dimethylaminopropyl)-N’-ethyl-
carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide (NHS) used for enzyme 
immobilization consist of 3 mM EDC and 5 mM NHS in KPi. Solutions were combined in a 1:1 
ratio (v/v) and substrates were immersed.  The solution of flurbiprofen and dapsone, used during 
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CYP2C9 immobilization, was 40 μM of each compound dissolved in KPi in a 1:1 ratio. 
Cryobuffer solution consists of KPi and glycerol (80:20, v/v) 
 
2.2.2.  Materials 
  
Diclofenac sodium, flurbiprofen, NHS, EDC, beta-nicotinamide adenine dinucleotide 
phosphate, reduced form (NADPH), beta-mercaptoethanol, 8-octanethiol (OT), 11-
mercaptoundecanoic acid (MUA), warfarin, nickel chloride  and N-phenylanthranilic acid were 
purchased from Sigma-Aldrich (Milwaukee, WI). 4’hydroxydiclofenac was purchased from 
Toronto Research Chemicals (Toronto, Canada). Cytochrome P450 reductase (CPR)was 
purchased from BD Biosciences. Purified CYP2C9 and dapsone were provided by Dr. Tim 
Tracy (Minneapolis, MN).  Polyacrylamide gels and gel loading and running buffer were 
purchased from Biorad (Hercules, CA). Unless otherwise noted, chemicals were purchased from 
Sigma-Aldrich. 
 
2.2.3.  PMMA Chip Fabrication 
For initial, proof of concept experiments, small (4 mm x 6 mm) PMMA chips were cut 
from a PMMA sheet (Goodfellow, Oakdale, PA) using an Epilog Legend EXT carbon dioxide 
laser (Golden, CO).  All of the PMMA chips were irradiated with UV light (Newport 
Corporation, Irvine, CA) (280 nm) for 15 minutes, per each side, prior to use.   
 
2.2.4. PMMA Plug-flow Bioreactor Fabrication  
The PMMA based bioreactor was fabricated by micromilled using a Sherline Model 2010 
milling station (Vista, CA) from PMMA plastic blanks (McMaster Carr, Elmhurst, IL).  The 
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milling of the channel was conducted at Protea Biosciences (Morgantown, WV).  Access holes 
and threads were all drilled with a standard drill press, and were designed to fit standard HPLC 
fittings (Upchurch Scientific, Oak Harbor, WA).  The milling schematic for plug-flow PMMA 
bioreactor is shown in the figure 1.  Both the top cover and milled channel were irradiated with 
UV light (Newport Corporation, Irvine CA) (280 nm) for 15 minutes on each side prior to fusing 
the two pieces together to finish the assembly of the PMMA bioreactor.   
 
 
  
Figure 2.1.  Milling schematic for the plug and flow bioreactor channel. Listed dimensions are 
given in millimeters (mm). 
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2.2.5.  PMMA-CYP2C9 Chip Preparation 
PMMA chips (section x.2.3) were sonicated in KPi for a total of 5 min and placed in a 
solution containing EDC/NHS in KPi (10 mL) for a total of 2h.  After activation of the surface 
carboxylic acids with NHS based esters, chips were rinsed KPi to remove excess EDC and NHS 
and were then treated with CYP2C9 (100 nM) in KPi containing a flurbiprofen and dapsone, 
overnight, to allow for covalent bonding of CYP2C9 to NHS-activated esters. Finally, PMMA-
CYP2C9 chips were rinsed in KPi before being stored in cryobuffer at -80°C prior to use.  
 
2.2.6.  PMMA-AcBzTacn-CYP2C9 Chip Fabrication 
PMMA chips (section x.2.3) were sonicated in KPi for a total of 5 minutes.  After 
sonication, chips were removed from the KPi solution and transferred to vials containing 
EDC/NHS in KPi (10 mL) and were allowed to react for 2 h.  Chips were rinsed with KPi and 
then were treated with (2 mL) AcBzTacn (20 mM) (A generous gift from Lisandra Martin, 
Monash University, Australia) previously dissolved in a potassium hydroxide solution (pH 10) 
for 30 hours.  After the surface was functionalized with AcBzTacn, the surface was treated with 
(10 mL) nickel chloride (100 mM) for 1 h. Finally, the PMMA chips were treated with a solution 
(2 mL) of CYP2C9 (100 nM) in KPi containing flurbiprofen and dapsone, overnight, to allow for 
Ni+2 coordinated immobilization of CYP2C9 to the PMMA surface. After the PMMA-
AcBzTacn-CYP2C9 construct was formed, chips were rinsed in KPi before being stored in 
cryobuffer at -80°C until use. All processes were performed under argon and at room 
temperature. 
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2.2.7.  Gold-OT/MUA-CYP2C9 Chip Fabrication.   
Silicon wafers containing 50 nm gold on 5 nm chromium were diced into approximately 
4 mm x 6mm chips and were sonicated in acetone for 5 minutes, rinsed with deionized water, 
and then soaked in Piranha solution (98% H2SO4: 30% H2O2, 3:1, v/v) at  room temperature for 
30 minutes. Chips  were then rinsed with deionized water, ethanol, and then soaked in an 
ethanolic solution of 8-octanethiol (75 mM) and 11-mercaptoundecanoic acid (25 mM) for 18 
hours to allow the SAM to form on the gold surface.  Excess thiols were removed by subsequent 
rinsing the chips with pure ethanol, 95% ethanol, water and finally KPi.  To bond the CYP2C9 to 
the SAM, the SAM-coated slides were immersed in a solution of EDC/NHS in KPi (10 mL) for a 
total of 2h.  After activation of the surface carboxylic acids with NHS based esters, chips were 
rinsed KPi to remove excess EDC and NHS and were then treated with CYP2C9 (100 nM) in 
KPi containing a flurbiprofen and dapsone, overnight, to allow for covalent bonding of CYP2C9 
to NHS-activated esters. Finally, Au-SAM-CYP2C9 chips were rinsed in KPi before being 
stored in cryobuffer at -80°C prior to use.  
 
2.2.8.  PMMA-CYP2C9 and Au-OT/MUA-CYP2C9 Chip  Metabolic Incubation 
Both Au-SAM-CYP2C9 and PMMA-CYP2C9 chips were immersed in solutions 
containing Cytochrome P450 Reductase (200 nM, final concentration) and diclofenac (250 µM, 
final concentration) in KPi buffer in glass vials.  To initiate the reaction, NADPH (250 µM, final 
concentration) in KPi was added, bringing the total reaction volume to 200 µL.  The incubation 
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mixtures were incubated in a water bath overnight (16 h) at 37°C. Positive control experiments 
(200 µl, final volume) were conducted with solution CYP2C9 (2.5 nM, final concentration) 
containing 10 µL of dilaurophosphatidyl choline (1 mg/mL).   
 
2.2.9.  Fabrication of PMMA-2C9 Bioreactor EDC-NHS Construct (Dynamic Application) 
After fabrication of the PMMA bioreactor and its exposure to ultraviolet radiation, the 
plug and flow channel was cleaned by flowing KPi (10 ml, 40 mM) through the PMMA block at 
a rate of 500 µL/h using a Harvard Apparatus Pump II syringe pump (Holliston, MA). Once 
complete, the channel was filled (2 mL) with EDC/NHS in KPi.  After the activation of the 
PMMA with the EDC/NHS mixture, the channel was rinsed with KPi (2 mL) for 2 hours at 
1mL/h. Next, CYP2C9 (10 mL, 100 nM) dissolved in flurbiprofen and dapsone (1:1,v/v) in KPi 
was delivered through the channel continuously for a total of 20 h at 500 uL/h. After CYP2C9 
immobilization, the channel was rinsed for a total 4 h with (2 mL) KPi at 500 uL/hr. 
 
2.2.10.  Fabrication of PMMA-2C9 Bioreactor EDC-NHS Construct (Static Application) 
Alternatively, a plug-flow bioreactor channel was fabricated using the same methods as 
above.  However, during application of CYP2C9, the plug-flow channel was filled with a 
CYP2C9 solution (2 mL, 500 nM) dissolved in flurbiprofen and dapsone (1:1,v/v) in KPi.  The 
CYP2C9 solution was applied to the channel in the absence of flow of CYP2C9 solution. After 
CYP2C9 immobilization, the channel was rinsed for a total 4 h with (2 mL) KPi at 500 uL/hr. 
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2.2.11.  Fabrication of PMMA-2C9 Bioreactor AcBzTacn Construct  
For fabrication of a PMMA based bioreactor containing AcBzTacn, the plug-flow 
channel was cleaned by flowing KPi (10 mL, 40 mM) through the PMMA block at a rate of 500 
uL/h using a Harvard Apparatus Pump II syringe pump (Holliston, MA). The bioreactor was then 
filled with EDC/NHS in KPi (2 mL) and allowed to react for 2 h.  After activation of the PMMA 
with the EDC/NHS mixture, the channel was rinsed with KPi at (2 mL, 1 mL/h). Next, 
AcBzTacn (2 mL, 20 mM) in aqueous potassium hydroxide solution (pH 10) was applied by 
filling the channel and allowing the mixture to react with the surface for 30 h. The bioreactor was 
then treated with KPi at (2 mL, 1ml/hr). After the channel was rinsed free of excess AcBzTacn, 
the bioreactor was treated with CYP2C9 (10 mL, 100 nM, 20 h, 500 µL/hr) in the presence of 
flurbiprofen and dapsone (1:1, v/v). Finally, the channel was flushed with KPi (500 uL/h, 4 h) to 
remove residual enzyme solution. 
 
2.2.12.  Metabolite Generation of PMMA-CYP2C9 Bioreactor 
The basic set-up for the generation of 4’OH diclofenac is shown in Figure 2. The syringe 
and pump were coupled to HPLC style fittings and PEEK tubing. The block was placed into a 
jacketed beaker which is coupled to a circulating water bath to maintain the internal temperature 
of the jacketed beaker at 37°C. The physical set up is described in figure 2. Generation of 
metabolites is initiated by pumping of a solution containing diclofenac sodium (250 µM, final 
concentration), NADPH (1mM, final concentration) and CPR (200 nM, final concentration) in 
KPi at 10mL, 500 µL/h, 20 h). KPi solution containing metabolite leaves the bioreactor channel, 
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the PEEK tubing was positioned over a fraction collector.  Fractions were continuously collected 
at a rate of one fraction per hour (500 uL) for a total of 20 h.  The syringe was then refilled with 
KPi pumped through the bioreactor (2 mL, 500uL/h, 4h) to remove residual metabolite from the 
channel.  The wash fractions were collected in the same procedure above, resulting in a total of 
24 fractions.  Fractions were centrifuged under, vacuum, to dryness using a Savant SC110 
Speedvac (Thermo-Fisher, Pittsburgh, PA). Once dry, samples were reconstituted in aqueous 
acetonitrile (5% v/v, 200 uL).  
   
Covered Jacketed Beaker 
+ PMMA Bioreactor 
Syringe + Pump Fraction Collector 
Circulating Water Bath 
(37°C)  
Figure 2.2.   Setup corresponding to plug-flow PMMA-based bioreactor. 
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2.2.13.  Chromatographic Detection of 4’hydroxydiclofenac 
Metabolic reactions and bioreactor fractions were quenched by spiking with (50uL) 
acetic acid (50 µL, HPLC grade) and an internal standard, N-phenylanthranilic acid in 
acetonitrile (50 µL, 5 µg/mL HPLC grade). Once completed, incubations were centrifuged 
(13,000 x g) for 10 min to precipitate protein. The supernatant (200 µL) was removed and loaded 
into vials for chromatographic analysis. Separation of metabolite and parent compound was 
conducted using a Waters Alliance 2965 separations module (Milford, MA).  Approximately 
10uL of analyte was injected on to a Agilent Zorbax SB C-18 (150 mm X 4.6 mm, 5 µm particle 
size) (Agilent Technologies, Santa Rosa,. CA.) . Substrate and metabolite were eluted at 
0.5ml/min using a mobile phase mixture of sodium acetate (75 mM, pH 5) and Acetonitrile 
(60:40, v/v).  Eluted compounds were analyzed by a Waters 2487 Dual Absorbance Detector 
with absorbance detection at 280 nm. Data was processed by Waters Empower ver 2.0 software 
(Waters Corporation, Milford, MA).  The peak corresponding to 4’hydroxydiclofenac was 
determined by comparison to a 4’-hydroxydiclofenac standard.  
 
2.2.14.  Immobilization of CYP2C9 Enzyme on Gold electrode.   
Gold-coated glass slides (EMF Films, Ithaca, NY) were sonicated in acetone for 5 
minutes, rinsed with deionized water, and then soaked in Piranha solution (98% H2SO4: 30% 
H2O2, 3:1, v/v) at 80o C for 15 minutes. The gold-coated glass slides were then rinsed with 
deionized water, ethanol, and then soaked in an ethanolic solution of 8-octanethiol (75 mM) and 
11-mercaptoundecanoic acid (25 mM) overnight to allow the SAM to attach to the gold surface.  
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Excess thiols were removed by rinsing the SAM bearing gold-coated glass slides with absolute 
ethanol and PBS, each, three times. In order to bond the CYP2C9 to the SAM, the SAM-coated 
slides were covered with KPi containing EDC/NHS.  The treated slides were then removed from 
the EDC/NHS solution and immersed in a KPi solution containing CYP2C9 (100 nM), 
flurbiprofen (40 µM), and dapsone (40 µM) for 24 hr. All processes were performed under argon 
and at room temperature.  
 
2.2.15.  Electrocatalytic Metabolism of Warfarin 
Au-(MUA/OT)-CYP2C9 electrodes were immersed in an oxygen-saturated KPi solution 
containing NaCl (154 mM).  A potential of -0.38 was applied using a potentiostat (Gamry 
Reference 600™, Warminster, PA), in the presence of a platinum wire (1 mm o.d.) counter 
electrode, an Ag/AgCl (3M KCl) reference electrode, and the CYP2C9-bonded gold electrode 
(CYP2C9-MUA/OT-Au) as the working electrode. The electrolysis was conducted for 2 hours.  
The electrode surface area was approximately 0.07 cm2 and electrolysis solutions were 
magnetically stirred (150 RPM).  The warfarin concentration in the electrolysis solution was 50 
uM.  Upon completion of the electrolysis, the solution was concentrated to dryness, dissolved in 
acetonitrile (2 mL), filtered, and then concentrated to dryness.  The residue was dissolved in KPi 
(200 uL), spiked with 7-ethoxycoumarin (50 µL, 1ug/ml) in acetonitrile, centrifuged (5 min @ 
13,000x g) and loaded into HPLC vials for chromatographic analysis.   
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2.2.16.  Reconstituted CYP2C9 Incubation with Warfarin 
Reconstituted CYP2C9 enzyme incubations with warfarin were conducted using enzyme 
prepared from insect cells infected with recombinant baculovirus containing a human 
CYP2C9*1 cDNA and rabbit NADPH-P450 reductase.  For these incubations, warfarin (50 µM) 
was incubated with CYP2C9 (125 nM) in KPi, phospholipid (1.6 mM, final concentration), CPR 
(250 nM, final concentration) all in a total volume of 200 µL.  Samples were pre-incubated for 3 
min at 37°C before the addition of NADPH (1mM, final concentration).  Incubations were 
conducted for 20 min at 37°C, quenched by the addition of 7-ethoxycoumarin (50 µL, 1 µg/mL) 
in acetonitrile as the internal standard.  The incubation mixture was then centrifuged (15 min @ 
13000 x g) to pellet proteins.  A total of 200 µL of the supernatant was then loaded into liquid 
chromatography vials for analysis.   
 
2.2.17.  Chromatographic Analysis of Warfarin Metabolites 
Analysis of warfarin and its metabolites was performed with a Waters Alliance 2965 
(Waters Corporation, Milford, MA) separations module using a Waters Symmetry column (150 
mm × 4.6 mm, 3.6 µm particle size, Waters Corporation, Milford, MA), eluting with aqueous 
phosphoric acid (0.5%) and acetonitrile (60:40, v/v, 1 mL/min), with fluorescence detection 
using a Waters 2475 dual channel fluorescence detector, (λex = 320 nm, λem = 415 nm). nm) and 
an injection volume of 10 µL.  All chromatographic analysis was performed using Empower ver. 
2.0 software (Waters Corporation, Milford, MA).  The peak corresponding to 7-hydroxywarfarin 
was determined by comparison to a 7-hydroxywarfarin standard. 
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2.3.  Results 
2.3.1.  Introduction 
In order to maximize metabolite production of the completed plug-flow bioreactor, 
several different parameters were optimized on PMMA chips.  Several PMMA chip  studies 
were designed to look at optimal fabrication of PMMA-CYP2C9 chips. These include 
concentration of CYP2C9 exposed to NHS-activated PMMA, length of attachment time of 
CYP2C9 to NHS- activated PMMA and finally two different attachment schemes. Parameters 
which gave optimal metabolite output were then used in the fabrication of the plug-flow 
bioreactor. 
 
2.3.2.  Variation of CYP2C9 Immobilization Concentration  
In order to determine optimal concentration of CYP2C9, largely to prevent over 
crowding of CYP2C9 present on the PMMA surface, and enhance CPR access to the CPR 
binding site on the covalently immobilized CYP2C9, we conducted experiments varying the 
concentration of CYP2C9.  PMMA chips were irradiated with UV light to cleave ester moieties 
within the PMMA polymer and form free carboxylic acids. Next, we incubated PMMA chips in 
EDC/NHS to from activated an NHS-ester, which will covalently bond any free amine in 
solution. Subsequently, we incubated the chips in 50, 100, 200 and 400 nM CYP2C9 
respectively to bond the CYP2C9 to the chips. The activity of each chip was then determined by 
measuring the metabolism of diclofenac, a probe CYP2C9 substrate (process is outlined in 
Figure 2.3).  
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Figure 2.3.  UV mediated cleavage of ester moieties present within the PMMA polymer. 
Subsequent EDC/NHS activation allows for the covalent linkage of CYP2C9 to the polymer 
surface. 
 
Figure 2.4 shows the metabolism data for solution controls and PMMA chips. In this 
figure, the solid black bar represents the positive control experiment containing roughly 0.5 pmol 
CYP2C9 in solution. Negative control experiments omitted NADPH for each respective 
attachment concentration. Metabolite formation, 4’hydroxydiclofenac, was not detected in the 
negative controls. 
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Figure 2.4.  Metabolic formations from PMMA chips prepared with different concentrations (50, 
100, 200, 400 nM) of CYP2C9 applied to EDC/NHS activated PMMA chips (grey). Solution 
incubation (black) contains 0.5 pmol CYP2C9 and dilaurophosphatidyl choline (black). All 
incubations contain CPR and NADPH. 
 
2.3.3.  CYP2C9 Attachment Time 
In addition to determining the optimal enzyme concentration to treat the PMMA surface 
with and thus optimize metabolite output, we ran a series of experiments to optimize the PMMA 
chip exposure time to CYP2C9. The results are shown in Figure 5. This experiment used UV 
activated PMMA chips (4 mm x 6 mm) treated with EDC/NHS and then CYP2C9 (100 nM) 
solution for different time periods (2, 4, 6, 8 and 24 hours). Negative control experiments 
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omitted NADPH for each respective attachment time. Metabolite formation, 
4’hydroxydiclofenac, was not detected in the negative controls. 
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Figure 2.5.  Incubation study optimizing CYP2C9 attachment time (2, 4, 6, 8, and 24 h) to an 
EDC/NHS activated PMMA chips.   
 
2.3.4.  CYP2C9 Attachment Type  
A third parmater varied in addition to using different solution concentrations of CYP2C9 
for protein attachment and different exposure times to optimize attachment, was to utilize two 
different attachment chemistries with the goal of optimizing metabolite production.  One method 
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involves using EDC-NHS conjugation to form a covalent bond with a free amine at the N-
terminus or on the surface of the protein.  The second method used Acbztacn, a molecule capable 
of chelating divalent cations such as Ni+2.  Once this complex coordinates these divalent cations 
to the Acbztacn moiety, it can then bind the remaining coordination sites of the chelated species 
(Ni+2) to bind a his-tag, present on the C-terminus of the enzyme. This provides a way to 
specifically bind the protein at a specific site, in contrast to the EDC-NHS coupling, where the 
binding site is somewhat ambiguous. Figure 2.6 shows the amount of metabolite formation for 
solution incubations (solid black), the previously described CYP2C9 immobilized to a gold-thiol 
self-assembled monolayer (bricked) and from UV-exposed, PMMA chips (solid gray) that used 
AcBzTacn. The immobilized CYP2C9 experiments directly compare the metabolic activity of 
enzyme immobilized with EDC/NHS versus Acbztacn.  Negative control experiments contain no 
NADPH for each respective attachment type and no metabolite was detected in any of these 
samples using our method of detection for 4’hydroxydiclofenac.    
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 Figure 2.6.  Comparison of metabolite production based on his-tag directed coordination 
(AcBzTacn) and covalent coupling (EDC/NHS) on gold-OT:MUA(3:1) self-assembled 
monolayer (bricked) or PMMA (grey). Incubations were conducted for 24 h. 
 
2.3.4.  Metabolite Production of Completed Bioreactor 
After fabrication of the plug-flow bioreactor channel and subsequent coupling of 
CYP2C9, CPR and NADPH were flowed through the bioreactor (500 uL/hour). Samples were 
collected (500 uL) and metabolite production in each fraction determined by HPLC (Figure 7).  
Analysis of two different coupling chemistries, filled circles, representing Acbztacn coupling, 
and an EDC-NHS coupled bioreactor, represented by the filled squares were compared.  Both of 
these bioreactors constructs were fabricated using a method where (10 mL) CYP2C9 (100 nM) 
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was flowed through the channel at a continuous rate (500 uL/hr) for a total of 20 hours.  In 
contrast, we have also monitored the production of metabolites based on an EDC-NHS based 
bioreactor which is treated with the same amount of CYP2C9 (1 nmol), however the enzyme is 
applied by filling the channel with a single volume of (2 mL) CYP2C9 (500nM), and is 
represented by filled triangles. Total metabolite production for each bioreactor were 1.) Acbztacn 
coupled (114.1 ng), 2.) EDC-NHS coupled (295.7 ng) (dynamic application) and 3.) EDC-NHS 
in the absence of flow (static application) through the channel during CYP2C9 application (437.3 
ng).  
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Figure 2.7.  Time course analysis of metabolite production by a CYP2C9 immobilized plug and 
flow PMMA bioreactor. His-tag directed coordination with Acbztacn (circles) is compared to 
plug and flow channels  fabricated using EDC/NHS covalent immobilization.  Further 
comparison of EDC/NHS immobilization techniques is shown by continuous injection (10 mL, 
continuously injected at 500 µL per hour for 20 h total) of CYP2C9 (100 nM) (squares) and 
static injection (2 mL, injected immediately, for 20 h) (triangles) of CYP2C9 (500 nM). 
 
 
2.3.6.  Alternative Bioreactor Generated Warfarin Metabolites 
An alternative approach to producing useful quantities of metabolite is to use the 
immobilize enzyme as an electrode.  Therefore, a model for a batch biochemical reactor was 
explored using an electrochemical cell with a gold electrode to which was attached CYP2C9 via 
an OT:MUA (3:1) self-assembled monolayer.  The electrochemical bioreactor was filled with 
warfarin (50 μM) in water, KPi and sodium chloride (154 mM) and held at a potential of -0.38 V 
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for a period of  2 h.  Metabolite formation in the control potential electrolysis of warfarin was 
compared with a solution incubation by HPLC and the data is shown in Figure 8.  Curve A in 
figure 8 is the chromatogram obtained from the solution incubation. As indicated in Figure 8, the 
major metabolite formed is 7-hydroxywarfarin (retention time 6.8 min).  A second peak, with a 
retention time of 6.4 min was not identified by may be 6-hydroxywarfarin. The dashed curve 
above Curve A is the negative control (-NADPH) and lacks the peak corresponding to the 7-
hydroxywarfarin. Curve B in Figure 8 is the chromatogram of the controlled potential 
electrolysis mixture.  The formation of the expected metabolite (7-hydroxywarfarin) is apparent 
(retention time = 6.8 min), as is a second peak (retention time = 6.4 min) that was also observed 
in the solution incubation.  A third peak (retention time = 4.2 min) is observed but was not seen 
in the solution incubation.  The identity of this peak is unknown.  Finally, the dashed curve 
above curve B is of the same system except that no electrochemical potential was applied to the 
system (negative control).   
 
  
 63
 
Figure 2.8. Chromatogram trace representing the production of warfarin metabolites. 
Chromatographic trace (A) represents solution incubation of CYP2C9 baculosomes in the 
presence of NADPH. Dashed chromatographic trace above (A) represents an NADPH-free 
CYP2C9 baculosome incubation. Chromatographic trace (B) represents warfarin metabolites 
generated from a CYP2C9 immobilized electrode. Dashed line above (B) represents 
electrochemical analyte when no potential is applied to the enzyme-electrode.   
 
2.4.  Discussion  
2.4.1.  PMMA Based Plug-Flow Bioreactor 
Here we present a novel method to generate drug metabolites by utilizing chemically 
immobilized P450 enzymes in plug-flow bioreactor construct.  The use of recombinant enzymes 
in bioreactor systems as described here, is an approach to generate specific metabolites, using a 
single P450 isoform of interest.  The bioreactor constructs presented here are very easy to 
fabricate and only relies on simple, well established procedures including bioconjugation 
chemistry and microfluidic fabrication techniques.  This is in contrast to previously described  
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methods to generate metabolites.  The primary alternative for production of metabolites often 
requires synthetic approaches entailing several steps and can be a very expensive, time 
consuming and labor intensive process. 
 We have attempted to optimize the coverage of enzyme on the surface by modulating the 
concentration of CYP2C9 present during the immobilization. We found that an optimal 
immobilization concentration of CYP2C9 to be around 100 nM.  We hypothesize that a lower 
concentration of CYP2C9 present for immobilization would likely generate a surface which to 
sparsely populated with enzyme, thus generating lower levels of metabolite produced when 
compared to the 100 nM attachment concentration.  In contrast, attachment of CYP2C9 at higher 
concentrations probably leads to a surface which is tightly packed with enzyme, thereby reducing 
the access of CPR to the CYP2C9 located on the surface.  
In addition to monitoring the concentration of P450 available for attachment, we also 
wanted to observe the amount of time the enzyme could be exposed to a PMMA chip without 
losing activity.  We see an increase in metabolite produced over a period of 24 hours, without 
losing activity of the CYP2C9 over the 24 hour period.  This indicates that the CYP2C9 is a 
fairly robust enzyme and does not lose activity over long periods of time at room temperature, 
making it an excellent candidate for use in the proposed bioreactor construct. The ability of 
CYP2C9 to remain active over a long period of time without losing activity will allow for 
fabrication of the bioreactor under low-flow conditions, which will expose the inside of the 
channel to decreased levels of shearing force, which should reduce CYP2C9 denaturation during 
the immobilization process. 
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In addition to having the enzyme immobilized in a covalent manner, a comparison was 
made to monitor the activity of chips using AcBzTacn based immobilization, which is based on 
Ni+2 mediated coordination of a C-terminal his-tag present on CYP2C9.  From experiments 
conducted on PMMA and gold-thiol SAMs, we demonstrate that Acbztacn immobilized protein 
showed greater activity when compared to the EDC-NHS conjugated chips. This may be a result 
of the enzyme being oriented in a more favorable binding orientation to interact with CPR. By 
specifically attaching to the C-terminus, the enzyme likely exists in a single orientation, whereas 
with the EDC/NHS covalent immobilization, the enzyme may be immobilized at the N-terminus 
but could also be immobilized to any one of numerous surface lysine residues that exist on the 
surface.  In turn this could affect the binding of CPR, as the CYP2C9 could potentially have this 
binding site blocked.  Moreover, the random orientation of the CYP2C9 on the surface could 
also block the substrate access channel, which would have a detrimental affect on the activity of 
the enzyme.  As a result, we chose to compare enzyme immobilization methods in plug-flow 
bioreactors to determine which of the methods is best for optimal metabolite production. 
However, in these experiments, much less metabolite is produced from the Acbztacn 
immobilized protein when compared to the EDC/NHS immobilized based bioreactor, suggesting 
that EDC/NHS immobilized CYP2C9 may be the optimal choice for the plug-flow bioreactor 
construct.  
Furthermore, experiments comparing the application method of CYP2C9 to the 
bioreactor channel were compared to evaluate metabolic activity of each bioreactor construct.  
Two different plug-flow bioreactors were compared, one where enzyme was applied and 
immobilized CYP2C9 by delivering 2 mL of CYP2C9 solution to the channel immediately.  The 
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second approach applied 10 mL of CYP2C9 solution from a syringe at a constant flow for a total 
of 20 hours.  Both systems were treated with an equivalent amount of CYP2C9 (1 nmol) to allow 
for proper comparison. Results of this experiment suggest the static application of CYP2C9 
produced more metabolite over the 24 hour experiment than the dynamic application of CYP2C9 
flowed through the bioreactor channel during immobilization of CYP2C9.   This may be 
attributed to enzyme crowding, where the static system generates a surface more evenly covered  
with CYP2C9.  In contrast, when the enzyme is continuously applied, a situation may arise  
where the CYP2C9 at the beginning of the channel could be tightly packed due to the high 
concentration of enzyme present at the beginning of the channel, in turn hindering CPR binding.  
Moreover, near the end of the channel we have a situation where enzyme at the end of the 
channel is much more dispersed, creating a situation where little enzyme is present to metabolize 
substrates. 
Previously, we have described that an excess of CPR is necessary to generate metabolites 
in immobilized chip systems70. This is, in large part, due to the localized nature of CYP2C9 (on 
the chip) in relation to the dispersed nature of the CPR through out the solution.  More to the 
point, in a typical incubation conducted in solution, it is common to use a 2:1 ratio of CPR:P450, 
as these two components are evenly mixed throughout the solution. However in the case with the 
enzyme immobilized on the PMMA chip, these two components are heterogeneously mixed, 
resulting in the requirement for excess reductase to achieve sufficient concentration at the 
surface and therefore generate enough metabolite to be able to reliably quantitate P450 mediated 
metabolite production. 
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In contrast, the plug-flow bioreactor was found to generate metabolite without having the 
large excess concentration of CPR required with the chip incubations. That is to say that the 
concentration of CPR applied to the channel during the metabolism experiment is approximately 
2 fold (2 nmol) greater than the amount of CYP2C9 that is applied through the channel during 
the immobilization experiment.  It is hypothesized that this difference may be due to the 
difference in surface area/volume ratio between the two systems.  The cross section of the plug-
flow channel is 1 mm by 1 mm and the channel is 2.1 m long. This generates a channel with an 
internal volume of approximately 2100 µL and a surface area of 8400 mm2. In comparison, the 
immobilized chip experiments, conducted in 200 µL of solution and contain an activated surface 
area of approximately of 48 mm2. In comparing the ratio of surface area to volume, we see the 
plug-flow bioreactor channel has a much higher ratio (4 mm2/µL) when compared to the 
immobilized chip system (0.24 mm2/µL). 
Further complicating the issue of CPR access is the reduced mixing present in the 
channel of a plug-flow bioreactor, particularly in the axial direction.  As a result, the impaired 
mixing of the reactant may contribute to poor interaction of CPR on the P450-PMMA surface.  
Moreover, the decreased mixing may also hinder mixing of other components necessary for P450 
mediated metabolism, such as NADPH, O2 and substrate.  The lack of proper and homogeneous 
mixing in plug-flow reactors may help to explain the low levels of metabolite produced (as a 
function of CYP2C9 concentration). 
Accordingly, it would be optimal to use a concentration of CPR such that there was a 
ratio of CPR:P450 based on our estimate of the amount of P450 immobilized to the channel. This 
significantly reduces the amount of CPR used in running the bioreactor, and has several 
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advantages including the reduced cost to run the bioreactor (10 fold less CPR in each incubation 
compared to chip based experiments). Second, this system more accurately reflects common in-
vitro experiments that typically use a 2:1 ratio of CPR:P450.  
 Further optimization of the bioreactor construct is still necessary before such a device is 
ready for commercialized use.  For example, the CPR:P450 ratio has not been optimized, nor has 
flow rate, as both of these parameters differ significantly between the proof of concept chips and 
plug-flow bioreactor construct. This is due in large part to the ratio of volume to surface area 
between the two systems.  In the immobilized chip system, we have optimized reductase 
concentrations that are approximately 20:1 (CPR:P450).  This largely based on previous 
calculations of enzyme concentration, determined electrochemically, by similar sized chips made 
with a (3:1) OT:MUA self-assembled monolayer on gold71, a construct that serves to simulate 
the chemistry present on the PMMA surface.  Additionally, we see similar levels of metabolite 
between both the PMMA and gold-immobilized systems and thus we crudely estimate the level 
of enzyme immobilized to the PMMA and gold-self-assembled monolayer construct to be 
similar.  At the present time a reliable method to quantitate enzyme levels present on a PMMA 
surface has not been found.  Unfortunately this hinders the optimization process of the PMMA-
P450 chip, and we will look to address this in future experiments. 
 Previously, several groups have attempted to make metabolite using plug-flow 
bioreactors using HLM preparations154,155. Advantages of the plug-flow bioreactor utilizing 
recombinant CYP2C9, when compared to systems including HLMs includes the fact that this 
bioreactor uses a single P450 isoform and could thus be used to form only the metabolite(s) of 
interest.  This is particularly advantageous when trying to generate a specific metabolite or 
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compound for toxicological studies or for use as an analytical standard. In contrast, HLM based 
systems contain the entire compliment of P450 enzymes present in the liver and thus will 
potentially form many metabolites.  In several instances, reactive and toxic metabolites are often 
not the dominant metabolite produced and are often generated in very low quantities.  The 
system we describe here could be designed, by using any P450 enzyme of interest, to target the 
formation of specific compounds and would allow for researchers to generate these compounds 
in sufficient quantities to provide more definitive answers pertaining to the toxic mechanism of a 
particular metabolite. Finally, the use of HLM based bioreactors, since multiple metabolites may 
form, increases the difficulty of separating the compounds generated, often requiring complex 
chromatographic separations to in order to collect all the metabolites of interest. Thus, it is likely 
that these HLM based systems are better suited for early stage screening and structural 
elucidation of metabolites. 
 However systems do exist that will generate large quantities of metabolite, particularly 
insect-cell based systems designed by Rushmore, et. al151.  These systems are efficient for 
metabolite production and can be tailored by transfection of a P450 baculosome into insect-cell 
lines to produce specific metabolites of interest.  Though several disadvantages of this system are 
still apparent and should be addressed.  First, to generate the cell line of interest, it is necessary 
to be skilled in the growth and maintenance of cell lines, as well as the adequate transfection of 
the cell line.  Additionally, if it happens that you are trying to generate a metabolite which 
produces some cytotoxic effect, for example, through DNA-damage, then this presents a 
situation where production of metabolite(s) in a cell based bioreactor becomes counter-
productive, because the metabolites may cause cytotoxic effects to cells in the bioreactor. 
 
  
 70
Moreover, compounds that are specifically designed to cause cytotoxic effects, such as 
chemotherapeutic agents, may be compatible with our system, as it remains a cell free system. 
 Additionally, bioreactors containing living cells used for the generation of compounds of 
interest have several issues associated to their use that makes them undesirable candidates for use 
in bioreactors, particularly when compared to immobilized enzyme constructs.  For one 
temperature issues are well know to plague batch and fed-batch bioreactors, and often require 
complex temperature control systems.  Additionally, cell-based systems will generate a 
tremendous amount of waste, which needs to be removed from the system in order to keep the 
bioreactor functional.   
The use of a plug-flow bioreactor based on PMMA conjugated P450 enzymes could be 
easily converted into a system for its commercial use.  Commercially available PMMA tubing 
can be found at extremely reasonable prices.  Purchasing commercially available tubing 
eliminates the need to mill PMMA blocks and hence the associated costs (time, labor, 
equipment). we avoid having to purchase a costly milling station and eliminate the time required 
by the mill the PMMA block.  Furthermore, it is possible to couple the PMMA tubing to HPLC-
like fittings, which could potentially assist in high throughput metabolite generation and gives 
the device additional functionality to be used as a screening tool in early drug development 
situations. Additionally, several functionalized PMMA tubes could be bundled and utilized in 
hollow fiber bioreactor constructs156, thus serving to further increase the metabolite output of 
PMMA immobilized P450 bioreactor.  
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2.4.2. Electrochemical Batch Bioreactor 
As an alternative to the production of metabolites with a plug-flow PMMA bioreactor, an 
electrochemical based system to generate metabolites was utilized.  This system replaces the 
electron source CPR/NADPH with  electrochemically supplied electrons via an enzyme-based 
electrode.  Based on the levels of metabolite produced in relation to the amount of P450 used in 
each system, the electrocatalytic oxidation of CYP2C9 substrates is far more efficient in 
comparison to the plug-flow bioreactor described above.  Additionally, only substrate and buffer 
salts are necessary to run the electrochemical mediated synthesis, creating a cost effective 
method to generate metabolite.  In contrast, the plug-flow bioreactor channel uses substantial 
amounts of P450 as well as CPR and NADPH to carry out the catalytic oxidation of a given 
substrate.  In the long run this is an extremely costly process, and future research and resources 
should likely be applied to optimize the P450-electrode based metabolite synthesis.   
The downside of this approach is that the presence of CPR and NADPH contribute to the 
regiospecificity of metabolites that are produced.  As a result, the electrochemical bioreactor may 
produce metabolites that would not be found when using CPR and NADPH.  Evidence for this is 
shown in Figure 2.8, where a peak corresponding to a warfarin metabolite(s) elutes at 4.2 min.  
The chromatographic peak seen here may be a result of a metabolite eluting from the column 
which is not typically produced by P450 enzymes in the presence of CPR/NADPH.  Conversely, 
it may be a result of two subsequent oxidations of a warfarin molecule by the P450-electrode.  
To compare the metabolic profile of warfarin produced electrocatalytically, we 
performed an incubation of CYP2C9 baculosomes in KPi containing NADPH and racemic 
warfarin. The retention times of the species of interest in each chromatogram as they relate to the 
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retention time of the internal standard peak, demonstrate the formation of 7-hydroxywarfarin. 
This is the major metabolite of CYP2C9-mediated metabolism of warfarin and here it was 
formed with the application of an electrical potential to an enzyme-immobilized modified gold 
electrode.  Moreover, the chromatographic traces suggest that the electrocatalytically driven 
metabolism of racemic warfarin also results in the formation of other metabolites commonly 
observed by CYP2C9 metabolism.  The solution metabolism appears to yield much greater 
amounts of metabolite than the electrochemically driven system, based solely on peak area. 
However, when comparing the relative enzyme content of the two systems, the CYP2C9 
baculosome incubation contained  approximately 25 picomoles of CYP2C9 whereas the 
covalently bound CYP2C9 electrode contains approximately 0.06 picomoles, nearly 500 fold 
less CYP2C971.  These findings suggest the electrocatalytically generated method of metabolite 
production is a far more efficient method of metabolite production when compared to the plug-
flow reactor. The preparation of metabolites using the plug-flow PMMA bioreactor, designed as-
is, becomes somewhat cost prohibitive, particularly when you take into account the amount of 
purified enzyme required and the minimal amount of metabolite that is ultimately produced is 
taken into account. 
 
2.4.3.  Conclusion 
In summary, we have shown the ability of immobilized CYP2C9 to produce drug 
metabolites of interest. The methods described herein provide a significant advantage over 
traditional organic synthesis in that we can produce the metabolites in a rapid and high-
throughput fashion, with a high level of regiochemical control. Additionally we can synthesize 
 
  
 73
metabolites without the use of harsh reagents, thus eliminating safety hazards presented by 
traditional synthesis.  We propose this as a novel system to produce large quantities of 
metabolites for pharmaceutical companies to conduct toxicity testing. We believe that this 
technique could be used to potentially save pharmaceutical companies time and money by 
eliminating the need to produce compounds in traditional medicinal chemistry laboratories 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 74
Chapter 3 
 
Nanostructure Device Designed to 
Control Aggregation between CYP2C9 
Enzymes 
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3.1.  Introduction 
Cytochrome P450 (P450) enzymes are a family of oxoferroreductase enzymes containing 
a heme moiety and are well known to be involved in the metabolism of a wide variety of 
endogenous and xenobiotic materials.  It is estimated that roughly 75% of all pharmaceutical 
compounds are metabolized by these enzymes and of these, approximately 90% are processed by 
five of the major human isoforms including CYP3A4, CYP2C9, CYP2C19, CYP2D6 and 
CYP1A2.39,157   
P450 enzymes involved in metabolism are present as a membrane bound proteins,  bound 
to the endoplasmic reticulum.  Early P450-mediated metabolism studies demonstrated that P450-
mediated metabolism required a membrane-bound complex containing a P450 enzyme and 
Cytochrome P450 reductase (CPR).  This finding provided a template for which model 
reconstituted systems would be developed and metabolism studies would be conducted3.   
Utilization of solution studies involving P450 enzymes has been extremely useful in determining 
and demonstrating overall drug safety. The approach provides an inexpensive and efficient way 
to determine viable drug candidates from the standpoint of drug metabolism (e.g., P450 binding, 
inhibition, toxic metabolite production) before more costly and extensive studies are undertaken.  
However, several issues still exist with solution systems for P450 incubations and metabolic 
differences between these model systems and in-vivo conditions have been described158.   
Among the issues which persist with respect to the current use of recombinant P450 
enzymes is the tendency of these enzymes to form aggregates with one another that may result in 
alterations in catalytic activity. It is believed that after purification from bacterial cells, the 
hydrophobic nature of these proteins tends to promote aggregation at the N-terminal membrane 
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associated domain60.  Experimentally, P450 aggregates can be dispersed by truncation of N-
terminal hydrophobic domains60,61, mutation of key residues involved in aggregation of P450 
enzymes63 through the use of non-denaturing detergents61,159, by incorporation into nanodiscs68, 
or by immobilization of the P450 enzyme to a solid substrate3,70,160. 
In instances where P450 enzymes are truncated to prevent the formation of 
aggregates60,61, the N-terminal domain is removed. In the case of truncated-CYP2E1, residues 3-
29 were removed from the protein sequence. Once removed this enzyme displayed a decreased 
tendency to form large aggregates and were restricted, primarily, to pentameric structures.  
However, given the nature of the N-terminal domain to associate with membrane-like structures 
and form an active redox complex with Cytochrome P450 Reductase, this mutation may also 
alter the catalytic activity and may not provide results that accurately reflect the true activity of 
the monomeric P450 enzymes. 
Additionally, mutations to key residues thought to be located in the F-helix or FG loop of 
P450 enzymes have also been addressed to reduce levels of aggregates63.  In studies involving 
mutations of the F-helix and FG-loop, it was found that some mutants displayed significantly 
decreased activity while others displayed increased activity over wild-type P450 enzymes.  
These observations could be the result of a reduced state of aggregation though it is also possible 
that it is an artifact of a change in the structure of the enzyme that produced the alteration in 
enzymatic activity. Utilization of mutations, therefore, may only be useful for assessing the 
mechanism of aggregation, and may not be suitable for studies that assess catalytic activity.  
An alternative approach to reduce or eliminate aggregation is to use detergents, such as 
Emulgen 913, within the incubation161.  By using this detergent at controlled concentrations, it 
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was demonstrated that monomeric forms of P450 could be produced.  Furthermore, it was shown 
that the formation of P450 aggregates can lead to large differences in the catalytic activity of 
CYP1A2.  This study demonstrated that large P450 aggregates are much less catalytically active 
than either the pentameric monomeric forms.  At the same time, it was also shown that 
pentameric aggregates of CYP1A2 were more catalytically efficient than monomers, when 
normalized for protein concentration. The caveat is that variation in the concentration the 
detergent may be a contributing factor to the poor activity seen in the monomeric forms, as this 
could hinder interactions with redox partner proteins, alter the membrane anchoring domains 
which are commonly used to generate a reconstituted incubation, or occupy/bind to the active 
site.  
Recently, nanometer-scale discoidal membranes have been synthesized by mixing 
membrane proteins with a helical belt protein to form a Nanodisc68,69.  This particular approach 
has been useful in the study of transmembrane proteins such as g-protein coupled receptors67 and 
P450 enzymes69. By controlling the size of the membrane disc, and thereby reducing the capacity 
of the discoidal membrane to bind large P450 aggregates, researchers have developed a system 
to reduce heterogeneity in P450 enzymes by  generating monomeric P450 enzymes for kinetic 
analysis68.   
We have developed approaches to reduce aggregation of P450 enzymes by selective 
immobilization of P450 enzymes to a solid surface70. In general, this platform will create a 
tethering point for P450 enzymes to remain stationary on the surface and in a monomeric form.  
However, given the tendency of mixed-thiol self-assembled monolayer films to produce non-
uniform (random distribution of thiols) mono-layers,90 it may be the case that domains will be 
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present in these self-assembled films that will carry a hydrophobic character and promote the 
formation of aggregates.  As discussed earlier, the likely mechanism of thiol aggregation is 
through the interaction of hydrophobic domains and these hydrophobic domains in SAMs 
promote localized aggregation and/or non-specific binding of proteins at a given point on the 
surface. As a result it is likely that an immobilized P450 (e.g., CYP2C9) is both bonded and non-
specifically bound to nanosized domains of octanethiol which are, in turn, bonded to the surface. 
There have been several recent advances in the creation of patterned nanostructures. The 
formation of these regular (patterned) nanostructures is effected through several different 
methods of fabrication including nano-imprint lithography162, near-field optical lithography163, 
dip-pen nanolithography164, scanning-probe microscope based nanoscale patterning165, self-
assembly of monolayers166, and pattern formation based on phase separation of polymers167. 
However as is the case with many of these methods, they often create nanostructures of non-
uniform size or periodicity or they are only optimized to form nanostructures over a very small 
area. As a result many of these techniques may be insufficient when it is desired to create a nano-
patterened surface of sufficient area such they bear sufficient enzyme for the generation of 
sufficient product for detection and quantitation.  
Here we describe a nanostructure device that, in principle, can be used to unequivocally 
control the aggregation state of CYP2C9.  In order to accomplish, we utilize polystyrene 
nanosphere based lithography168 to generate nanostructures of uniform size (here, 100 nm) and 
periodicity (500nm, presented here) over a large area such that approximately 100 billion 
‘nanowells’ are present in an area of 1 X 1 cm. This is sufficiently large to ensure that enough 
enzyme is present on the surface (~ 100 fmol) to detect metabolite by conventional methods 
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(HPLC, LC/MS). By immobilizing enzymes to this nanostructure device, we can unequivocally 
control the state of aggregation of these P450 enzymes to provide insight into the relationship of 
aggregation on catalytic activity.  
 
3.2.  Materials and Methods 
3.2.1.  General 
Unless otherwise noted, phosphate buffer (KPi) was made by mixing 40mM solutions of 
both dibasic and monobasic potassium phosphate such that the resulting solution of mixed 
components had a measured pH of 7.4.  Running buffer for SPR experiments includes the 
addition of sodium chloride (150 mM, final concentration) to KPi buffer and shall be referred to 
as phosphate buffered saline (PBS). The solution of flurbiprofen and dapsone, used during 
CYP2C9 adsorption, was 40 μM of each compound dissolved in KPi in a 1:1 ratio. The 
cryobuffer solution consists of KPi and glycerol (80:20, v/v) 
 
3.2.2.  Materials 
Diclofenac sodium, flurbiprofen, beta-nicotinaminde adenine dinucleotide phosphate, 
reduced form (NADPH), 8-octanethiol (OT), (11-mercaptoundecyl)tri(ethylene glycol), and N-
phenylanthranilic acid were purchased from Sigma-Aldrich (Milwaukee, WI). 
4’hydroxydiclofenac was purchased from Toronto Research Chemicals (Toronto, Canada). 
Cytochrome P450 reductase (CPR) was purchased from BD Biosciences (San Jose, CA). 
Purified CYP2C9 and dapsone were provided by Dr. Tim Tracy (Minneapolis, MN).  N-
octyltrimethoxysilane and 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane were purchased 
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from Gelest (Morrisville, PA).  Microscope cover slides were purchased from VWR (Radnor, 
PA). SPR substrate holders were purchased as part of an SIA Au kit from GE Healthcare 
(Pitscataway, NJ). Gold coated glass microscope slides were purchased from Evaporated Metal 
Films (Ithaca, NY). 
 
3.2.3.  SPR Film Fabrication. 
Microscope cover slides (40 mm x 24 mm, No. 2) (VWR, Radnor, PA) were cut into 12 
mm x 10 mm rectangles and were loaded into a Temescal BJD-2000 (Edwards Vacuum, 
Phoenix, AZ) system with an Inficon XTC/2 deposition controller (Inficon, East Syracuse, NY) 
for metal evaporation.  The chamber was pumped down to a pressure ≤ 1.0 x 10-5 Torr.  The 
system was set to a voltage of 10.0 kV.  Typical currents were approximately 40 mA for titanium 
and 80 mA for gold.  All metals were purchased from the Kurt J. Lesker Company (Clariton, 
PA).  Samples were rotated 1-2 RPM in the chamber to ensure uniform coverage. A crystal 
monitor with gold 6 MHz piezoelectric crystals (Kurt J. Lesker Co.) were used to monitor metal 
thickness during evaporation. 
Emission current was first allowed to stabilize at 12-13 mA to melt metal sources.  Upon 
stabilization, the current was slowly ramped up 5 mA until the metal began to melt.  Once the 
metal was ready, the shutter was opened and evaporation onto the SPR substrates would begin.  
The deposition rate onto the samples was controlled by adjusting the emission current and was 
typically maintained at 0.3-0.5 Å/s.  The Inficon XTC/2 deposition controller automatically 
closed the shutter when the desired final thickness had been reached.  The emission current was 
slowly turned down until it reached 0 mA.  Upon completion of each metal evaporation onto a 
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sample, the chamber was brought back to atmospheric pressure and samples were left inside to 
cool for 30-60 minutes before removal.  
 
3.2.4.  X-ray Photoelectron Spectroscopy Analysis 
XPS analysis performed with a Physical Electronics VersaProbe 5000 XPS (Chanhassen, 
MN), which was equipped with an EA125 energy analyzer. Photoemission was stimulated by a 
monochromated Al Κα X-ray (1486.6 eV). Nitrogen 1s (N1s) core level scans were scanned 
from 411-391 eV. Carbon 1s (C1s) core level scans were scanned from 299-279 eV. Electron 
counts were analyzed every 0.1 eV for high resolution core-level scans. Spectra (C1s, N1s) were 
acquired for the protein-adsorbed and nano-array samples using a pass energy of 58.7 eV. Peak 
binding energies were referenced to the Au 4f peak at 84.0 eV. 
 
3.2.5.  Gold-thiol Self-assembled Monolayer Fabrication 
Thin films of gold coated microscope slides (XPS analysis) or gold coated microscope 
cover slides (SPR analysis) were rinsed in distilled water (x3) and ethanol (x3) before being 
submerged in solutions containing octanethiol (10mM, 5mL total volume) or (11-
mercaptoundecyl) tri(ethylene glycol) (10 mM, 5 mL total volume) dissolved in 100% ethanol 
overnight (16 h). Once complete, gold-SAM films were rinsed with ethanol (x3) and distilled 
water (x3) and were dried under a gentle stream of nitrogen. 
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3.2.6.  Silicon Dioxide-silane Self-assembled Monolayer Fabrication 
Thin films of silicon dioxide (10 nm) on gold coated microscope slides (XPS analysis) or 
gold coated microscope cover slides (SPR analysis) were rinsed in distilled water (x3) and 
ethanol (x3) and anhydrous toluene (x3) before being submerged in solutions containing N-
octyltrimethoxysilane (6 mM, 5 mL total volume) or 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane (6 mM, 5 mL total volume) dissolved in 
anhydrous toluene containing triethylamine (1%, v/v) overnight (16 h). Once complete, silane-
SAM films were rinsed with anhydrous toluene (x3), ethanol (x3), and distilled water (x3) and 
were dried under a gentle stream of nitrogen. 
 
3.2.7.  SPR Binding Analysis 
SPR substrates chips, with pre-formed self-assembled monolayers, were taped down with 
double sided tape to SPR substrate holders acquired from a Biacore SIA Au chip kit.  Assembled 
SPR cartridges were loaded into a Biacore X100 SPR (GE Healthcare, Pitscataway, NJ) for 
analysis.  SPR experiments were conducted with a continuous flow of (PBS) at 10 µL/min.  
Running buffer was flowed over the sensor surface for a total of 90 sec followed by CYP2C9 in 
PBS (100 nM, 10 µL/min) for 480 sec, and then running buffer for an additional 480 sec.   
 
3.2.8.  Quantitation of CYP2C9 Surface Coverage 
 Quantitation of approximate surface coverage was determined by measuring response 
values before (90 sec) and after (700 sec) injection of CYP2C9 to determine ΔRU. Values were 
selected at time points before and after injection that would allow sufficient stabilization of the 
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SPR system. It has been approximated in the literature that a change of one response unit (ΔRU) 
is equivalent to 1pg/mm2 protein coverage169.  
 
3.2.9.  Adsorbed Enzyme Constructs 
Gold coated microscope slides containing thiol or silane SAMs described above, were 
treated with CYP2C9 (100 nM) dissolved in KPi (1 mL, total volume) overnight (16 h). Once 
complete, protein treated SAM surfaces were rinsed in KPi (x3) and distilled water (x3) and were 
dried under a gentle stream of nitrogen.  
 
3.2.10.  Preparation of Adsorbed CYP2C9 Constructs for Metabolic Incubation   
Silicon wafers containing 50 nm gold on 5 nm chromium were diced into approximately 
4 mm x 6mm chips and were sonicated in acetone for 5 min, rinsed with deionized water, and 
then soaked in Piranha solution (98% H2SO4: 30% H2O2, 3:1, v/v) at room temperature for 30 
minutes. Chips were then rinsed with deionized water, ethanol, and then soaked in an (20 mL) 
ethanolic solution of OT (10 mM), EG3 (10 mM) or a 3:1 ratio of OT to mercaptoundecanoic 
acid (MUA) (10 mM total thiol concentration) for 18 hours to allow the SAM to form on the 
gold surface. Excess thiols were removed by subsequent rinsing the chips with pure ethanol, 95% 
ethanol, water and finally KPi. To bond the CYP2C9 to the OT/MUA SAM chip, the SAM-
coated slides were immersed in a solution of EDC/NHS in KPi (10 mL) for a total of 2 h. Chips 
with SAMs which do not covalently bond CYP2C9 (OT + EG3) were treated with KPi for 2 h 
instead of the EDC/NHS mixture. To bind CYP2C9, chips were rinsed in KPi and were then 
treated with CYP2C9 (100 nM) in KPi containing a flurbiprofen and dapsone, overnight, to 
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allow for binding of CYP2C9 to the SAM surface. Finally, Au-SAM-CYP2C9 chips were rinsed 
in KPi before being stored in cryobuffer at -80°C prior to use. Incubation procedure used to 
assess metabolic activity is shown in section 3.2.13. 
 
3.2.10.  Nano-array Fabrication 
A large-area close-packed polystyrene sphere monolayer template was prepared. Briefly, a 
silicon substrate (> 15 mm × 15 mm) with a resistivity of > 2000 Ω cm−1 (p-type, 111◦ 1◦, 
undoped) was pretreated in piranha solution (H2O2:H2SO4, 3:7, v/v) for 1 h (Caution: piranha 
solution reacts violently with organic chemicals). The Si chip was then sonicated in a mixture 
solution (NH3:H2O2:H2O, 1:1:5, v/v) for 1 h to obtain a hydrophilic surface. Polystyrene 
spheres (PS) (500 nm diameter) were purchased from Thermo-Fisher Scientific (Waltham, MA). 
The 10% (w/v) aqueous solution of PS was diluted by mixing with an equivalent amount of 
ethanol prior to use. Approximately 5 μl of this PS suspension solution was dispensed onto the 
pretreated silicon substrate. The sphere covered silicon chip was then slowly immersed into 
deionized water in a glass Petri dish to release the PS spheres from the Si surface to form a self-
assembled close-packed PS monolayer on the water surface. A gold chip that was pretreated in 
the piranha solution (H2O2:H2SO4, 3:7, v/v) for 10 min was dipped into water and then slowly 
pulled out of the water surface. As a result, a close-packed PS monolayer was transferred onto 
the gold substrate from the water surface. To etch the PS monolayer present on the gold surface, 
a March PX-250 Plasma Asher (Nordson Corporation, Westlake, OH) was utilized, power 50 
watt, at 110 mtorr for 5-30 min to reduce the size of the polystyrene spheres. After reducing the 
PS radius, a thin film of SiO2 was deposited by e-beam evaporation as described above. The 10 
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nm deposition was conducted at 5-10 Å/s. Finally, samples were soaked in an ethanol solution 
and sonicated for 30 min to remove the PS monolayer.  
 
3.2.11.  Nano-array Imaging 
Image characterization of the morphology of the nano-array was conducted with a 
Hitachi S-4700 Field Emission Scanning Electron Microscope (Hitachi High Technologies 
America, Inc., Pleasanton, CA).  Atomic Force Microscope (AFM) images were generated using 
a Veeco SPM (Veeco, Plainview, NY). 
  
3.2.12.  Metabolic Incubation of the Nano-array  
Nanohole array chips were immersed in solutions containing Cytochrome P450 
Reductase (200 nM, final concentration) and diclofenac (250 µM, final concentration) dissolved 
in KPi buffer contained in Eppendorf tubes.  To initiate the reaction, NADPH (1 mM, final 
concentration) in KPi was added (final volume 1 mL).  The mixtures were incubated in a water 
bath overnight (16 h) at 37°C. Positive control experiments (1 mL, final volume) were conducted 
with solution CYP2C9 (2.5 nM, final concentration) containing dilaurophosphatidyl choline (50 
µL, 1 mg/mL). Incubations were quenched with glacial acetic acid (250 μL) containing N-
phenylanthranilic acid (internal standard) in acetonitrile (250 µL, 5 µg/mL HPLC grade).  Once 
incubations were completed, they were dried down (Savant SC110 Speedvac (Thermo-Fisher, 
Pittsburgh, PA)). Once dry, samples were reconstituted in (200 µL) sodium acetate buffer (75 
mM, pH 5) and acetonitrile (60:40, v/v), and loaded into HPLC vials for analysis. 
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3.2.13.  Chromatographic Detection of Diclofenac 
Metabolic reactions were quenched by spiking with acetic acid (50 µL, HPLC grade) and 
N-phenylanthranilic acid (internal standard) in acetonitrile (50 uL, 5 µg/mL HPLC grade). 
Incubation mixtures were then centrifuged (13,000 x g) for 10 min to precipitate protein the 
supernatant (200 µL) was removed and loaded into vials for chromatographic analysis. 
Separation of metabolite and parent compound was conducted using a Waters Alliance 2965 
separations module (Milford, MA).  Approximately 10 µL of analyte was injected on to a 
Agilent Zorbax SB C-18 (150 mm X 4.6 mm, 5 µm particle size (Agilent Technologies, Santa 
Rosa,. CA.)). Substrate and metabolite were eluted at 0.5 ml/min using a mobile phase mixture 
of sodium acetate (75 mM, pH 5) and acetonitrile (60:40, v/v).  Eluted compounds were analyzed 
on a Waters 2487 Dual Absorbance Detector at 280 nm. Data was processed using the Waters 
Empower ver. 2.0 software (Waters Corporation, Milford, MA).  The peak corresponding to 4’-
hydroxydiclofenac was determined by comparison to a 4’-hydroxydiclofenac standard. 
Approximate retention times for diclofenac, 4’-hydroxydiclofenac and N-phenylanthranilic acid 
were 23.4 mins, 10.2 mins, and 20.5 mins respectively.  
 
3.3.  Results 
3.3.1.  Biocatalysis of Diclofenac by Adsorbed CYP2C9 
 
The goal here is to selectively immobilize CYP2C9 to a SAM that is, in turn, bonded to a 
gold surface and, at the same time, prevent “non-specific binding to silicon dioxide. If this is the 
can be achieved then the CYP2C9 will be solely located in the nano-array well. Our approach 
was to first demonstrate that binding was dependent on the functional groups of the SMA that are 
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exposed to the medium.  It has been well demonstrated in the literature that hydrophobic proteins 
tend to strongly bind to alkyl groups but not to PEG terminated SAMs170,171.  Furthermore, it has 
been reported that thiols will bond to gold and not silicon (as long as dilute solutions are used). 
Consequently, the bottom of the nano-array well will bear an alkanethiol SAM and the remainder 
of the chip, PEG-silane. 
SAMs were prepared that were solely composed of octane thiol (OT) or 11-
mercaptoundecyl-triethylene glycol (EG3), treated with a solution of CYP2C9 and the resulting 
chip used in to effect metabolism of diclofenac.  The data are shown in Figure 1.  The data from 
three control experiments are shown, CYP2C9 in solution with and without NADPH, and our 
standard Au-(OT/MUA)-CYP2C9 chip (CYP2C9 bonded to MUA with NHS/EDC70).  Chips 
with OT SAMs produced metabolite (4’-hydroxydiclofenac) at about 75% of the level produced 
in solution or on the Au-(OT/MUA)-CYP2C9 chip while the SAM comprised of EG3 produced 
metabolite at about 10-15% of this level.  Thus, the OT layer appears to adsorb CYP2C9 much 
more strongly than did the EG3 SAM.  Alternatively, both SAMs may bind similar amounts of 
CYP2C9 but when bound to the EG3 SAM the enzyme activity is less than when bound to the 
OT SAM.   
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Figure 3.1.  Effect of SAM composition on metabolic activity of CYP2C9.  Solution mixtures 
contained CYP2C9, CPR, diclofenac and phospholipid.  Chip immobilized mixture were 
comprised of gold chips with the indicated SAM, bound (OT and EG3) or bonded ((3:1) 
OT:MUA) CYP2C9, diclofenac, CPR and NADPH.   
 
3.3.2.  SPR Characterization of CYP2C9 Adsorption 
In order to explain the trend in the metabolic data presented in Figure 1, an SPR 
experiment was designed to monitor adsorption of CYP2C9 to model surfaces. The adsorption of 
CYP2C9 to the OT and EG3 SAMs was monitored in real time by SPR spectroscopy. In Figure 
2A is shown the sensorgrams obtained for the adsorption of CYP2C9 to OT (black) or EG3 
(gray) SAMs. Figure 2B displays the sensorgrams for CYP2C9 adsorption to silane containing 
SAMs made of either n-octyltrimethoxysilane (black) or 2-[methoxy(polyethyleneoxy)propyl] 
trimethoxysilane (gray) For each experiment, sensor surfaces were equilibrated with running 
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buffer. Then CYP2C9, in running buffer, is injected on to the surface of the sensor (arrow 1), the 
interaction of CYP2C9 with SAM allowed to occur for approximately 480 seconds, and then 
returned to running buffer (arrow 2) alone. Each sensorgram trace is an average of three separate 
injections and each injection measurement was conducted on a freshly made SPR sensor film.  
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Figure 3.2.  SPR sensorgram comparing interaction of CYP2C9 with self-assembled monolayers 
produced from A. Gold-thiol self-assembled monolayers (octanethiol) (black) and (11-
Mercaptoundecyl)tri(ethylene glycol) (gray) and B. Silane-silicon dioxide self-assembled 
monlayers (n-octyltrimethoxysilane (black) and 2-[methoxy(polyethyleneoxy)propyl]trimethoxy 
silane (gray)). Each sensorgram trace represents an average of 3 separate experiments. 
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The change in response (ΔRU) is determined by subtraction of the response value taken 
before protein injection (t = 90 sec), from the response observed at the end of the run (t=700 sec) 
after protein injection had ceased.  Previous studies conducted with radioactive proteins172 
suggest that a change in response (ΔRU) of 1 RU correspond to a coverage of protein equivalent 
to 1 pg/mm2. Values of ΔRU and the corresponding protein coverage obtained from the 
sensorgrams in Figures 2A and B are compiled in Table 1.   
 
Table 3.1.  Observed ΔRU and Calculated Protein Coverage on Various SAMsa 
 
Self-assembled Monolayer ΔRU Protein Coverage 
(ng/mm2)b 
Octanethiol (OT) 
 
5853 ± 150 5.853 ± 0.15  
(11-Mercaptoundecyl)tri(ethylene glycol) 
(EG3) 
 
260 ± 230 0.260 ± 0.23  
N-Octyltrimethoxysilane 
 
2287 ± 480 2.287 ± 0.48  
2-[Methoxy(polyethyleneoxy)propyl] 
trimethoxysilane 
109 ± 100 0.109 ± 0.10  
Values calculating the difference between the baseline response during buffer washes over the 
sensor surface both before (90 s) and after (700 s) the injection of CYP2C9 injection.b A change 
in response (ΔRU) of 1 RU corresponds to a protein coverage of approximately 1 pg/mm2. 
 
 
3.3.3.  XPS Characterization of CYP2C9 Adsorption 
We also determined protein adsorption to a variety of self-assembled monolayers using 
XPS.  XPS provides information concerning the bond types, and, therefore, the identity of the 
atoms that are present on a surface.  Since amide bonds are unique to bound protein (i.e., not 
otherwise present in the SAM or supporting substrate), N1s core spectra, which corresponds to 
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binding energies in the range of 412 to 392 eV, were measured to determine if protein was 
present on the SAMs. Minor contributions to the N1s spectra are expected, arising from the 
guanidium group of arginine, primary amine groups on lysine, proline, glutamine, and 
asparagine, secondary amine groups of tryptophan and histidine. Information regarding the peak 
binding energy of various N-containing bonds is shown in Table 2.  Electron counts were taken 
approximately every 0.1 eV and each spectrum represents the summation of 15 successive scans. 
XPS spectra of CYP2C9 treated OT (black) or EG3 (gray) SAMs on gold are shown in Figure 
3A. CYP2C9 adsorption to silane self-assembled monolayers made from either n-
octyltrimethoxysilane (black) or 2-[methoxy(polyethyleneoxy)propyl] trimethoxysilane  (gray) 
are shown in Figure 3B.  
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Figure 3.3.  X-ray photelectron spectra comparing N1s core level scans of CYP2C9 adsorbed to 
self-assembled monolayers comprised of A) octanethiol (black) and (11-
Mercaptoundecyl)tri(ethylene glycol) (gray) on gold and B) N-octyltrimethoxysilane (black) and 
2-methoxy(polyethyleneoxy)propyl] trimethoxysilane (gray) on silicon dioxide. Each spectrum 
is the sum of 15 scans. 
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Table 3.2.  XPS Bond energies (N1s) 
Chemical Bond Peak energy (eV) 
N-C 399.5 
N-H 399.8 
N-C(O) 399.6 
N=C 398.9 
 Approximate energy of N1s electrons as a function of bonding environment. All values were 
obtained from an online XPS database173 
 
 
3.3.4.  AFM Imaging of Nano-array 
AFM images of the nano-array surface before SAM functionalization are shown in Figure 
4. The diameter, as determined by AFM, of each of the nanowells comprising the array is 
approximately 100 nm. The periodicity of nanowells is approximately 500 nm. Areas which 
appear lighter in color are regions which are coated in silicon dioxide. Darker regions represent 
the nano-hole and contain exposed gold at the bottom of the well structure.  
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Figure 3.4.  Atomic force images of the nanowell array structure. 
 
3.3.5.  SEM Imaging of Nano-array 
The SEM image of the nanohole surface is shown in Figure 5. The use of low 
magnification (Figure 5A) of the sample area demonstrates the regularity of the pattern over a 
large area. At higher magnification of the sample (Figure 5B) provides confirmatory evidence of 
the dimensions of the nanowell (diameter 100 nm) and periodicity between (500 nm). 
 
  
 96
 
 
A B
Figure 3.5.  (A) Low magnification scanning electron micrograph (SEM) of the nanowell array. 
(B) High magnification SEM image of the nanowell array. 
 
 
3.3.6.  XPS Characterization of Nano-array Fabrication 
 
The nanowell array was examined by XPS at each step of the fabrication process.  
Spectra for the bare array (1), with the OT self-assembled monolayer (2), with the octanethiol 
and 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane self-assembled monolayers (3) and 
finally the completed nanowell array with both the octanethiol and 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane self-assembled monolayers and adsorbed 
CYP2C9 (4) are shown in Figure 6. Here, we measured both the C1s (Figure 6A) and N1s 
(Figure 6B) core-level spectra of the nanowell array. Spectrum 3 in Figure 6A, exhibits a 
characteristic double peak indicated by an arrow, suggesting the presence of a C-O bond, which 
implies that a SAM consisting of 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane has 
formed on the nano-array surface.  For reference, information regarding the peak binding 
energies of various C-containing bonds, including C-O, is shown in Table 3.3. Spectrum 4 in 
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Figure 6B, suggests the presence of nitrogen on the surface, highlighted by the arrow, supporting 
the claim that CYP2C9 is adsorbed to the nano-array surface.  See Table 3.2 for information on 
peak energies of N-containing bonds.   
Table 3.3.  XPS Peak Bond Energies (C1s) 
Chemical Bond Peak energy (eV) 
C-C 284.6 
C-O 286.5 
C-H 284.6 
C=O 286.8 
C(O)-N 288.2 
C-N 285.7 
C-S 286.8 
Approximate energy of C1s electrons as a function of bonding environment.  All values were 
obtained from an online XPS database173 
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Figure 3.6.  XPS spectra of the A) C1s core level spectra and B) N1s core level spectra obtained 
during fabrication of the nanowell chip bearing OT and 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane and CYP2C9.  Successive spectra (from 
bottom) in each panel are of the step-by-step fabrication of the nanowell array and are 1) the bare 
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array, 2) (1) + OT SAM, 3) (2) + 2-[methoxy(polyethyleneoxy)propyl]-trimethoxysilane, 4) (3) + 
CYP2C9. 
 
 
3.3.7.   Metabolic Activity of the Completed Nano-array. 
After the adsorption of CYP2C9 to the nano-array, we evaluated the metabolic activity of 
the CYP2C9 bearing array probing for the biotransformation of diclofenac into its primary 
CYP2C9-mediated metabolite, 4’hydroxydiclofenac. Nano-array incubations contained NADPH 
(1 mM, final concentration) as an electron donor, CYP2C9, CPR, and diclofenac.  The solution 
control was similarly constituted but also contained phospholipid.  Negative control experiments 
omitted NADPH. Results are shown in Table 2. 
 
Table 2.4.  CYP2C9-Nanowell Metabolite Production from Diclofenac.a 
Experiment Conditions 4’hydroxydiclofenac (ng/mL) 
Solution CYP2C9 (+NADPH)  12.56 ± 0.56 
Solution CYP2C9 (-NADPH) ND 
Nanowell CYP2C9 (+NADPH) 7.41 ± 0.32 
Nanowell CYP2C9 (-NADPH) ND 
Incubation conditions:  Solution incubations contained CYP2C9 (0.5 pmol), CPR (10 pmol), 
phospholipid (1 mg/ml) and diclofenac (250 µM).  Positive controls also contained NADPH (1 
mM).  Nanowell incubations contained CYP2C9 adsorbed Nano-array, CPR (10 pmol), 
diclofenac (250 µM). Metabolite formation determined by HPLC.   
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3.4.  Discussion 
Cytochrome P450 enzymes are well known to form aggregates in solution.  It is thought 
that aggregation can have a profound effect on the catalytic activity of the enzyme.  In order to 
unequivocally control the state of aggregation of a P450 enzyme, several different approaches 
have been taken including truncation of N-terminal domains believed to be involved in 
aggregation, mutation of key residues thought to be involved in aggregation, the use of 
detergents, binding to Nanodiscs®, and immobilization of the protein to a solid surface.  Of the 
above listed approaches to inhibit the aggregation of these proteins, only binding to Nanodiscs® 
or immobilization to a solid substrate provides a reasonable means to maintain the protein in a 
non-aggregated state without modifying the incubation conditions (e.g., addition of detergent) or 
modification of the protein (e.g., N-terminal truncation, FG loop or F helix residue mutation, 
etc).  Further, only immobilization to a solid substrate will permit the selective creation of more 
complex structures (e.g., homo- or hetero-dimers, trimers, etc.).  As a result we have proposed a 
nanostructure device  and have been developing it that is designed to unequivocally control the 
state of aggregation of P450 enzymes by providing a surface to which P450 enzymes bind, or 
bond, in an area with well defined surface topology. 
A key feature of nanowell arrays is the bottom of the nanowell is gold while the 
surrounding material is silicon dioxide, permitting the selective formation of OT SAMs on the 
floor of the nanowell surrounded by a thin layer (10 nm) silicon dioxide bearing a 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane SAM.  By doing this the nanowell surfaces 
have be selectively functionalized.  The hydrophobic nature of OT presents a SAM for P450 
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binding while the polyethylene glycol bearing silane is resistant to protein adsorption and will 
thus promote the adsorption of a P450 of interest in the nanowell. 
Cross-reactivity of silane to gold as well as thiol to silicon dioxide is a potential issue, 
making the step wise fabrication of the device occur in a specific order (thiol first, silane 
second). Literature sources have suggested that formation of silane based SAMs on gold do in 
fact occur174.  As a result, the OT containing SAM was first formed on gold by treating with OT 
first.  This will block the silane from forming a self-assembled monolayer on gold.  Thiols have 
shown the ability to form self-assembled monolayers on oxide surfaces175, however, it has been 
demonstrated that thiol-based self-assembled monolayers form on oxide surfaces only when thiol 
solutions are neat, or by chemical vapor deposition. This evidence suggests that our thiol should 
not interact (i.e., form a SAM) with the silicon dioxide surface. 
The fabrication of a nanostructure device on a large scale (1 cm x 1 cm) is a potentially 
difficult task to accomplish. With this in mind, we designed the nanostructure array to be 
reusable, utilizing the strong association of the CYP2C9 to the surface, but also a strong 
detergent will dissociate the CYP2C9 from the surface and permit the CYP2C9 to be washed 
away from the surface. In turn, this should make the nanostructure device reusable.  This will be 
especially useful, as the complexity of device fabrication increases as the dimensions of the 
nano-well decrease.   
In order to verify the activity of the CYP2C9 that was adsorbed to a surface, a study was 
conducted where CYP2C9 was adsorbed to a surface using both OT and EG3 thiol-based SAMs. 
These chips were created and transferred to a reaction incubation after allowing for CYP2C9 to 
adsorb, in the presence of flurbiprofen and dapsone, to the surface of interest. The adsorbed 
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constructs were compared to a well described immobilized P450 enzyme construct and 
demonstrate statistically similar levels of metabolite formation.  Furthermore, the data shown in 
Figure 1 indicates that greater activity is seen in gold chips bearing OT SAMs as opposed to EG3 
based SAMs. This result can be explained by two potential hypotheses, either 1) PEG-thiol based 
SAMs have significantly less CYP2C9 bound to the surface than their OT counterparts, 
providing less enzyme for metabolic transformation or 2) PEG-based SAM’s interact with 
CYP2C9 in, for an example, a denaturing manner to reduce the metabolic activity of the 
adsorbed CYP2C9.  Under the premise that the first hypothesis is correct, it is reasonable that 
very little CYP2C9 adsorption to PEG monolayers may occur, and that most of the CYP2C9 
adsorbs to the exposed silicon dioxide wafer on the back of the chip176, explaining the minimal 
activity seen with EG3 thiol-based SAM’s. 
SPR was used to resolve the question of whether or not CYP2C9 was being adsorbed to 
SAMs of OT and EG3 on gold as well as 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane 
and N-octyltrimethoxy silane on silicon dioxide. SPR spectra for these experiments are shown in 
Figure 2A for SAMs formed on gold, and Figure 2B for SAMs formed on silicon dioxide.  Here, 
SPR  spectra demonstrate, in real time, that CYP2C9 is non-specifically adsorbing to OT based 
self-assembled monolayers on gold as well as N-octyltrimethoxysilane based self-assembled 
monolayers formed on silicon dioxide-covered gold SPR films. Interestingly, in triplicate 
experiments comparing the relative response between the two hydrophobic SAM’s, thiol based 
SAMs demonstrate a two-fold greater response when compared to silane based SAMs.  
Differences in response seen between gold-thiol and silicon dioxide-silane SAMs may be 
attributed to the fact that gold-thiol SAMs typically form well ordered films on the gold surface.  
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In contrast, silane based self-assembled monolayers often exhibit decreased order in formation, 
either through insufficient packing91 or through self polymerization177 of silane components.  It is 
hypothesized that differences in observed SPR response regarding the adsorption of CYP2C9 to 
SAMs of OT or N-octyltrimethoxy silane may be attributed to differences in the formation of 
SAMs on two chemically different materials, gold and silicon dioxide.  
SPR experiments were also designed to observe an in situ interaction of CYP2C9 on 
hydrophobic thiol- and silane-based SAMs, SPR films were also functionalized with PEG based 
SAMs (EG3 and 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane) and subsequently their 
interaction with CYP2C9are shown in Figure 2A and Figure 2B and the sensorgrams indicate 
that the binding of CYP2C9 to PEG-based SAMs is significantly less, roughly 20-fold, than the 
analogous binding to the hydrocarbon (OT and N-octyltrimethoxy silane) based SAMs.  The 
small response observed for CYP2C9 exposure to PEG-based SAMs is likely due to 
imperfections in the SAM structure, or bare areas which may allow adsorption of CYP2C9. 
 In addition to looking at an in situ interaction of CYP2C9 to a SAM, we can also measure 
protein coverage by monitoring SPR response. Studies conducted with radioactive-labeled 
proteins established that a change in response equal to 1 RU is approximately equal to a 1 
pg/mm2 coverage of protein172. From this, we can measure the amount of CYP2C9 adsorbed to 
either gold-thiol or silane-silicon dioxide SAMs by monitoring the difference in response before 
and after protein injection, as determined from the SPR data (see Table 3.2).  We observed 
coverage levels for hydrophobic SAMs composed of OT (5.853 ± 0.15 ng/mm2) or N-
octyltrimethoxy silane (2.287 ± 0.48 ng/mm2).  In contrast PEG SAMs made from EG3 (0.260 ± 
0.23 ng/mm2) or 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane (0.109 ± 0.10 ng/mm2) 
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solutions exhibit significantly lower coverage, supporting the idea the CYP2C9 will bind to the 
well, avoiding the areas of silicon dioxide in between each gold well.  
 SPR experiments are useful to demonstrate protein adsorption to surfaces, however, SPR 
experiments are run over a short time (540 sec) of protein exposure.  As a result, the experiment 
designed here may provide a poor model for chip-preparation, which typically expose the surface 
to CYP2C9 overnight (16 h).  To counter this, several model surfaces were incubated and 
functionalized with the same SAMs in the SPR experiment (see Figure 2).  These samples were 
analyzed with XPS, and the respective spectra are shown in Figure 3 (A and B).  The XPS 
spectra suggest that binding of CYP2C9 to surfaces with OT and N-octyltrimethoxysilane exhibit 
high levels of protein adsorption based on peak intensity as compared to either EG3 or 2-
[methoxy(polyethyleneoxy)propyl]trimethoxysilane SAMs.  The results suggest that SPR data is 
reflective of CYP2C9 binding under long-term immersion. Furthermore, data indicates that 
CYP2C9 will likely have a preference for the hydrophobic SAM present in the bottom of the 
nanostructure array and will selectively bind in the nanowell..  
 XPS measurements at each step of the fabrication of the array proved to be extremely 
useful to monitor the changing characteristics of the array surface.  The data shown in Figure 6A 
shows changes in peak shape corresponding to alterations in C1s core electron energies as a 
function of bonding environment.  Figure 6A spectrum (1) is an XPS spectrum of the bare array.  
The peak present in this spectrum is likely due to atmospheric hydrocarbons non-specifically 
adsorbed to the surface.  Next in Figure 6A spectrum (2), we see the addition of OT SAM to the 
array surface.  Interestingly, Figure 6A spectrum (3) displays a characteristic “double peak” after 
the application of PEG silane self-assembled monolayers178.  Values of binding energy 
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associated to C1s bonds can be observed in Table 3.3.  The peak values for C-C and C-H, both 
284.6 eV differ from the peak energy from C-O bonds (286.5) and give rise to the double peak 
characteristic seen in Figure 6A spectrum (3). This data indicates that the silane self-assembled 
monolayer containing 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane has formed on the 
device. Furthermore, the XPS data, after the addition of protein in spectrum 4, suggests CYP2C9 
is adsorbed to the surface.  This result is by the data shown in confirmed in Figure 4.  XPS 
spectra of N1s core level electrons is shown in Figure 6B and spectrum (4) indicates that after 
the treatment of the device with CYP2C9 enzyme is bound to the surface.  
 After fabrication of the array surface and immersion in CYP2C9, the nano-array was 
immersed in an incubation containing CPR and NADPH to probe for metabolic activity.  Data 
regarding the metabolic activity of the completed array was compiled and shown in Table 3.4.  
Samples containing the completed nanoarray with NADPH indicate that CYP2C9 remains active 
when bound to the array surface.  In contrast, when NADPH is absent from the incubation 
mixture, no metabolite (4’-hydroxydiclofenac) was detected.  This data suggests that CYP2C9 
immobilized on the array surface in the presence of natural co-factors and co-enzymes remains 
metabolically active.  Moreover, when compared to data obtained from solution incubations 
containing dilaurophysphatidyl choline, array incubations generate metabolites with identical 
retention times, indicating that the metabolite formed is likely 4’-hydroxydiclofenac. 
 The amount of CYP2C9 bound to the nano-array can be roughly predicted by making a 
few assumptions regarding the array.  If the diameter of CYP2C9 is approximately 7 nm in 
diameter, then the number of congruent circles (CYP2C9) which can fit inside a larger 100 nm 
circle (nano-array well) has been probed with computer programs179.  These programs predict the 
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ideal packing of a perfectly circular CYP2C9 in a 100 nm nano-array well results in 231 
enzymes present in a single well. Perfect packing of the congruent CYP2C9 is likely not 
occurring.  If this were the case, little room would be available in the nano-array well to allow 
for CPR binding. As a result, we can approximate the number of enzymes in a single well to 
correspond to the median value of enzymes (115 enzymes) that may be found in a well. 
Assuming that the distribution of enzymes in wells across the surface is uniform, the median 
number of enzymes present in a well corresponds to an average value of enzymes present in a 
well.  With that assumption, we can predict the amount of 100 nm nano-array wells, with 500 nm 
periodicity, in a 1 cm by 1 cm square to be 4 x 108 wells.  Assuming 200 enzymes are in each 
well, the total amount of enzyme present on the surface is 4.6 x 1010 enzymes, around 75 
femtomoles. Typical pharmaceutical incubations utilize anywhere from 1 to 10 picomoles of 
enzyme, approximately 10- to 100-fold more enzyme than is present on the device.  As a result, 
metabolic incubations utilizing the nanostructure array will likely need to employ high-turnover 
substrates or ultra-sensitive detection methods to evaluate metabolic activity. 
 In summary, here we have shown the interaction of CYP2C9 with a variety of SAMs. 
The information presented here suggests that CYP2C9 should be localizing to areas of 
hydrophobic SAM at the bottom of the nano-well structure. In turn, we aim to fabricate this 
device with further reduced the dimensions of the nano-array elements, so that it is only capable, 
unequivocally, of binding a single P450 enzyme per well with space for CPR. In turn, we would 
like to make use of this device to make predictions regarding in-vivo metabolism of drugs, using 
this improved in-vitro model. Ultimately this device may be very useful in early drug 
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development and may help to answer mechanistic discrepancies between actual in-vivo drug 
metabolism and traditional in-vitro solution experiments 
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Chapter 4 
 
Gold-Immobilized CYP2C9 as a 
Platform to Characterize Protein-
Protein Interactions Occuring in P450 
Enzymes 
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4.1.  Introduction 
Cytochrome P450 (P450) enzymes are a family of oxoferroreductase enzymes containing 
a heme moiety and are well known to be involved in the metabolism of a wide variety of 
endogenous and xenobiotic materials.  It is estimated that roughly 75% of all pharmaceutical 
compounds are metabolized by these enzymes and of these, approximately 90% are processed by 
five of the major human isoforms including CYP3A4, CYP2C9, CYP2C19, CYP2D6 and 
CYP1A2.39,180   
 P450 enzymes are expressed in all tissues, but have particularly high expression in 
hepatic tissues, where most of the oxidative drug metabolism is thought to be carried out.  To 
form a functional complex, cytochrome P450 enzymes combine with cytochrome P450 reductase 
(CPR) to transfer electrons from NADPH to the heme-center of the P450 enzyme77,181, where 
drugs are then oxidized.   Cytochrome P450 reductase interacts with the cytochrome P450 in a 
1:1 stoichiometry to generate metabolite, however it has been described in the literature that 
ratios of P450 to CPR in hepatocytes are around 10:1 to 20:1182.  As a result, interaction between 
P450 enzymes may be occurring to facilitate sub-optimal concentrations of CPR in hepatocytes.  
 Protein-protein interactions between different P450 enzymes in hepatocytes has been 
demonstrated to occur in-vivo183. In order to provide some insight into interactions which may be 
occurring between specific P450 isoforms, several groups have used recombinant expressed 
enzyme incubations to probe for catalytic alterations exacerbated by the presence of a second 
P450 isoform. Specific instances of protein-protein interactions between P450 enzymes include 
interactions between CYP2C9 and CYP2C19 in the oxidation of methoxychlor79, CYP2C9 and 
CYP2D6 in the oxidation of both flurbiprofen and dextromethorphan81,  CYP2C9 and CYP3A4 
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in the metabolism of testosterone and naproxen184,  and  CYP2B4 and CYP1A2 in oxidation of 
7-pentoxyresorufin185.  
 Reconstituted incubations containing recombinantly prepared P450 enzymes are 
advantageous in that concentrations of individual enzymes present in an incubation can be easily 
controlled.  Furthermore, with the advent of recombinant DNA technology, interactions between 
virtually any combinations of P450s can be studied.  However, reconstituted P450 enzymes are 
prone to aggregation, which has been shown to affect the catalytic activity of P450 enzyme65.  
Furthermore, it is conceivable that protein-protein interactions observed using reconstituted 
solution incubations may be an artifact of the system.  In short, alterations in catalytic activity 
occur as a result of the mixed enzyme aggregates that form in model systems which may exhibit 
different catalytic activities than would be observed by monomeric proteins interacting alone.   
Ideally, it would be useful to selectively control the aggregation state of a P450 enzyme 
and monitor their interaction with other P450 enzymes. Several attempts have been made to 
reduce aggregation of P450 enzymes, including mutation of key residues involved in P450 
aggregation63, truncation of N-terminal domains60,61, the use of detergents designed to keep P450 
enzymes in monomeric form65, formation of discoidal lipid nanostructures referred to as 
Nanodiscs®68 which limit the area of membrane to dimensions which can only bind a single 
enzyme, and finally immobilization of the protein to a solid surface70. With the exception of 
Nanodiscs® and immobilization to solid surfaces, the techniques used to control aggregation 
either change the incubation conditions or mutate the enzyme, and the resulting data may be a 
poor reflection of in-vivo conditions and activity. 
 
  
 111
Current techniques for characterizing protein-protein interactions include monitoring 
changes in catalytic activity79,81,184,185, Förster resonance energy transfer (FRET)186, isothermal 
titration calorimetry187, circular dichroism188 and surface plasmon resonance (SPR) 189.   FRET 
and other related techniques carry the disadvantage of requiring protein modifications (e.g., 
attachment of a fluorescent tag), which may affect protein-protein interactions. Other techniques 
such as circular dichroism and isothermal titration calorimetry often require large volumes of 
highly concentrated samples to properly establish biophysical constants of protein-protein 
interaction.  On the other hand, SPR based experiments that monitor protein-protein interactions 
have the advantage of requiring small amounts of sample.  Additionally, P450 enzymes have 
similar refractive indicies associated with them, thus samples are already “tagged” in their native 
form. Moreover, the change in response in SPR experiments is linearly proportional to the 
amount of protein (change in refractive index) at the surface, providing what equates to an 
extremely sensitive mass sensor.   
Typically, SPR experiments are conducted on a carboxymethyl-dextran gel which is 
grafted on to a thin film of gold, necessary for the SPR experiment190. The carboxymethyl-
dextran gel contains free carboxylic acid groups which will allow for the surface to be bonded 
with proteins and/or enzymes once activated with N-hydroxysulfosuccinimide (NHS) and N-(3-
Dimethylaminopropyl)-N’-ethyl-carbodiimide hydrochloride (EDC).  Unfortunately, the physical 
nature of the carbohydrate on the surface, which makes it difficult to image with AFM, which is 
used as a secondary measure of the protein aggregation state.  However, gold with self-
assembled monolayers (SAMs) can be used in SPR, permitting the direct transfer of the methods 
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we have described in the literature70, where the formation of monomeric P450 enzymes has been 
shown.  
Here we describe the interaction of solution CYP2D6 with an OT/MUA immobilized 
CYP2C9.  Using SPR, both on (ka) and off rates (kd) for solution CYP2D6 to immobilized, 
monomeric CYP2C9 are determined and thereby KD (kd/ka).  Additionally we demonstrate that 
the presence of CYP2D6 has little effect on the metabolism of flurbiprofen by immobilized 
CYP2C9.  This is in contrast with solution data that has been published, which suggests that the 
addition of CYP2D6 to incubations of flurbiprofen and CYP2C9 causes an inhibitory effect. We 
hypothesize that the differences observed are a result of the decreased state of aggregation of the 
Au-OT/MUA immobilized CYP2C9 versus solution incubations. In turn, the work presented 
here could be useful in describing protein-protein interactions between cytochrome P450 
enzymes and may help make better predictions of in-vivo drug metabolism based on improved 
in-vitro models. 
 
4.2.  Materials and Methods 
 
4.2.1  General 
Unless otherwise noted, chemicals were purchased from Sigma-Aldrich. Inorganic 
phosphate buffer (KPi) was made by mixing 40mM solutions of both dibasic and monobasic 
potassium phosphate until the solution of mixed components had a measured pH of 7.4. Mixtures 
of EDC and NHS used for enzyme immobilization consist of 3 mM EDC and 5 mM NHS in KPi 
for chip-based incubations.  SPR experiments utilize 0.4 M EDC and 0.1 M NHS in KPi. In both 
instances, solutions were combined in a 1:1 ratio (v/v) and applied to surfaces of interest.  
Running buffer for SPR experiments contains 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
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acid (HEPES) (10 mM), sodium chloride (154 mM), sodium ethylenediaminetetraacetic acid 
(EDTA) (3 mM), and TWEEN 20 (0.05%) and is referred to as HBS+EP. The solution of 
flurbiprofen and dapsone, used during CYP2C9 immobilization, was 40 μM of each compound 
dissolved in KPi in a 1:1 ratio. Cryobuffer solution consists of 80:20 KPi to glycerol (v/v). 
 
4.2.2. Materials 
Flurbiprofen, NHS, EDC, Nicotinamide adenine dinucleotide phosphate reduced form 
(NADPH), β-mercaptoethanol, 8-octanethiol (OT), and 11-mercaptoundecanoic acid (MUA) 
were purchased from Sigma Aldrich (Milwaukee, WI). Cytochrome P450 reductase was 
purchased from BD Biosciences (Franklin Lakes, NJ). Purified CYP2C9, CYP2D6, 
4’hydroxyflurbiprofen, 2-fluoro-4-biphenyl acetic acid and dapsone were provided by Dr. Tim 
Tracy (Lexington, KY).   
 
4.2.3.  SPR Substrate Fabrication 
Microscope cover slides (40 mm x 24 mm, No. 2) (VWR, Radnor PA) were cut into 12 
mm x 10 mm rectangles (SPR experiment) or 3” silicon wafers (metabolic experiment) 
(University Wafer, South Boston, MA) and were loaded into a Temescal BJD-2000 (Edwards 
Vacuum, Phoenix, AZ) system with an Inficon XTC/2 deposition controller (Inficon, East 
Syracuse, NY) for metal evaporation.  The chamber was pumped down to a pressure ≤ 1.0 x 10-5 
Torr.  The system was set to a voltage of 10.0 kV.  Typical currents were approximately 40 mA 
for titanium and 80 mA for gold.  All metals were purchased from the Kurt J. Lesker Company 
(Clariton, PA).  Samples were rotated at 1-2 rpm in the chamber to ensure uniform coverage. A 
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crystal monitor with gold 6 MHz piezoelectric crystals (Kurt J. Lesker Co.) were used to monitor 
metal thickness during evaporation. 
The emission current was first allowed to stabilize at 12-13 mA to melt metal sources.  
Upon stabilization, the current was slowly ramped up an additional 5 mA until the metal began 
to melt.  Once the metal was molten, the shutter was opened and evaporation onto the SPR 
substrates began.  The deposition rate onto the samples was controlled by adjusting the emission 
current and was typically maintained at 0.3-0.5 Ǻ/s.  The Inficon XTC/2 deposition controller 
automatically closed the shutter when the desired final thickness had been reached.  The 
emission current was slowly turned down until it reached 0 mA.  Upon completion of each metal 
evaporation onto a sample, the chamber was brought back to atmospheric pressure and samples 
were left inside to cool for 30-60 minutes before removal.  
 
4.2.4.  Gold-thiol self-assembled monolayer fabrication (SPR) 
Thin films of gold coated microscope cover slides (SPR analysis) were rinsed with 
distilled water (x3) and ethanol (x3) before being submerged in a solution (12 mL total) of 
octanethiol (10mM, 9mL total volume) and 11-mercaptoundecanoic acid (10 mM, 3 mL total 
volume) (3:1) dissolved in 100% ethanol overnight (16 h). The gold-SAM films were then rinsed 
with ethanol (x3) and distilled water (x3) and then dried under a gentle stream of nitrogen. 
 
4.2.5.  SPR Immobilization 
SPR sensor substrates, with pre-formed self-assembled monolayers, were taped down to 
SPR substrate holders acquired from a Biacore SIA Au chip kit using double-sided tape.  
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Assembled SPR cartridges were loaded into a Biacore X100 SPR (GE Healthcare, Pitscataway, 
NJ) for analysis.  SPR experiments were conducted with a continuous flow of (HBS+EP) at 10 
µL/min.  Running buffer was flowed over the sensor surface for a total of ~200 sec to generate a 
baseline value.  Next the sensor surface was treated with a 1:1 mixture of EDC (0.4 M) and NHS 
(0.1 M) for a total of 480 sec.  The sensor surface was rinsed with HBS+EP for 270 sec. Next the 
surface was treated with CYP2C9 (100 nM), dissolved in HBS+EP, for 420 sec and then rinsed 
with HBS+EP for 270 sec.  Unreacted NHS esters were destroyed by treating with a solution of 
ethanolamine (1 M), dissolved in water, for 540 sec and were rinsed with HBS+EP (270 sec).  
Finally, the surface was rinsed with cetyltrimethylammonium bromide (CTAB) (3.9 mM), 
dissolved in water, for 540 sec and then with HBS+EP (270sec). The negative control (reference) 
alternated the order of injection so that ethanolamine was first injected, followed by CYP2C9. 
HBS+EP washes serve to rinse the surface, and, also are designed for intermittent response 
measurements. 
 
4.2.6.  Binding of Immobilized CYP2C9 with CYP2D6 
 After the formation of the immobilized CYP2C9 sample and reference flow cells, SPR 
sensor surfaces were treated with varying concentrations of CYP2D6 (0 nM, 5 nM, 10 nM, 50 
nM,  100 nM, 500 nM). To reduce large fluctuations in the bulk refractive index of CYP2D6 
containing solutions and to allow for proper blank-subtraction of kinetic sensorgrams, protein-
free cryobuffer was added to generate solutions of CYP2D6 which are identical to one another 
with the exception of CYP2D6 concentrations. Contact times for CYP2D6 solutions were 
approximately 180 sec followed by a dissociation period of 900 sec, during which time the 
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sample cell washed with HBS+EP. Changes in response values are represented as a difference, 
where the response in the reference flow cell is subtracted from the sample flow cell to correct 
for non-specific interaction of CYP2C9 with the surface of interest.  Fitting of kinetic data was 
accomplished by Biacore X100 evaluation software.     
 
4.2.7.  Gold-OT/MUA-CYP2C9 Chip Fabrication.   
Silicon wafers containing a 50 nm gold layer on a 5 nm chromium layer were diced into 
approximately 4 mm x 6mm chips, sonicated in acetone for 5 minutes, rinsed with deionized 
water, and then soaked in Piranha solution (98% H2SO4: 30% H2O2, 3:1, v/v) at  room 
temperature for 30 minutes (CAUTION: Piranha solution reacts violently with organic 
chemicals). Chips were then rinsed with deionized water, ethanol, and then soaked in an 
ethanolic solution containing a 3:1 ratio of OT (10 mM) and MUA (10 mM) overnight to allow 
for the SAM to form a bond and attach to the gold surface.  Non- specifically adsorbed thiols 
were removed by rinsing the chips with 100% ethanol, 95% ethanol, water and finally KPi.  To 
bond the CYP2C9 to the SAM, the SAM-coated slides were immersed with KPi (10 mL) 
containing EDC/NHS (2 mM and 5 mM, respectively).  The treated chips were then removed 
from the EDC/NHS solution and immersed in a KPi (4 mL) solution containing CYP2C9 (100 
nM), flurbiprofen (40 µM), and dapsone (40 µM) for 24 hr. All processes were performed under 
argon and at room temperature. CYP2C9 chips were then immersed and removed from a KPi 
solution before being stored in cryobuffer at -80°C until use.  
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4.2.8.  Metabolic incubation of CYP2C9 chips with flurbiprofen 
Gold-OT/MUA chips bearing CYP2C9 were immersed in vials containing Cytochrome 
P450 Reductase (200 nM, final concentration), cytochrome b5 (100 nM) and flurbiprofen (250 
µM, final concentration) in KPi buffer.  To initiate the reaction, samples were spiked with 
NADPH (250 µM, final concentration) in KPi, bringing the total reaction volume to 200uL. The 
vials were then incubated for ~16h at 37°C (water bath) at 37°C. Positive control experiments 
(200 µl, final volume) replace Gold-CYP2C9 chips with solution CYP2C9 (2.5 nM, final 
concentration) containing 10 μL of dilaurophosphatidyl choline (1 mg/mL).  Final concentrations 
of CYP2D6 added to incubations of CYP2C9 are (0.75 nM (0.3:1)), (1.25 nM (0.5:1)), (2.5 nM 
(1:1)) and (5 nM (2:1)). The amount of CYP2D6 added assumed the amount of bonded CYP2C9 
was ~0.5 pmol. 
 
4.2.9.  Chromatographic Detection of 4’hydroxyflurbiprofen   
Flurbiprofen containing incubations were quenched with  acetonitrile containing 200 
ng/mL 2-fluoro-4-biphenylacetic acid (internal standard) (50 µl) and a 50% phosphoric acid 
solution (50 µl).  Samples were centrifuged for 10 min and supernatant (200 μL) was loaded into 
liquid chromatography vials.  Chromatography was conducted using a Waters Alliance 2965 
separations module, an Alltech Econosphere C-18  column (150mm X 4.6mm, 5um particle 
size)(Grace-Davison, Deerfield, IL) with a 10 μL injection volume.  Substrate and metabolite 
were eluted at 1 ml/min (60:40) mobile phase mixture of potassium phosphate (20 mM, pH 3) 
and acetonitrile.  Eluted compounds were detected with a Waters 2475 fluorescence detector (λex 
= 260nm, λem = 260nm). Data was processed by using the Waters Empower software (ver 2.0). 
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The peak corresponding to 4’hydroxyflurbiprofen was determined by comparison to a 
4’hydroxyflurbiprofen standard. Approximate retention times for flurbiprofen, 4’-
hydroxyflurbiprofen and 2-fluoro-4-biphenyl acetic acid were 15.2 mins, 10.1 mins, and 6.3 
mins respectively.  
 
4.3.  Results 
4.3.1.  SPR based real-time immobilization of CYP2C9 to OT:MUA  
Real time immobilization of CYP2C9 to a self-assembled monolayer containing a 3:1 
ratio of OT to MUA was conducted on a thin film of gold (50 nm) and was monitored by SPR 
spectroscopy in Figure 4.1.  Initially the sensor surface was treated with running buffer to 
generate a baseline response value.  Next the surface was treated with a 1:1 EDC:NHS mixture 
to react with free carboxylic acid groups presented by the SAM. The surface was subsequently 
rinsed with running buffer in preparation for the next step.  In the active flow cell (black line), 
the surface was treated with CYP2C9 followed by ethanolamine to block unreacted NHS esters, 
and demonstrate an increase in response relative to the baseline generated in the initial washing. 
In contrast, the blank flow cell was treated with ethanolamine after EDC-NHS activation 
followed by CYP2C9 treatment.  By treating with ethanolamine first, activated NHS esters will 
react with the amine group of the ethanolamine, preventing further functionalization with 
protein.  Both surfaces were finally treated with CTAB, which has been demonstrated to remove 
non-specifically bound proteins191. After CTAB rinsing, the surface was rinsed a final time in 
running buffer.  Surfaces treated with CYP2C9 followed by ethanolamine demonstrate a positive 
response (≈ 375 RU) compared to a blank immobilized flow cell which should be unable to 
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covalently bind protein (≈ -200 RU).  The positive response indicates protein is covalently 
immobilized to the SAM.   
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Figure 4.1.  Real time immobilization of CYP2C9 using SPR. The active flow cell (FC2) 
containing CYP2C9 was treated with CYP2C9 before ethanolamine to promote covalent bonding 
of CYP2C9 to the SAM. Negative control experiment used to generate the blank flow cell is 
treated with ethanolamine before CYP2C9 to block covalent binding of CYP2C9 to the surface.   
 
4.3.2.  Binding of CYP2D6 to immobilized CYP2C9 
The preparation of both sample and reference flow cells in the SPR, as described above, 
allows for measurement of the binding between the immobilized CYP2C9 and solution CYP2D6 
(Figure 4.2). Solutions of varying concentrations of CYP2D6 were flowed over both the sample 
flow cell, containing immobilized CYP2C9 as well as the reference flow cell to correct for non-
specific interaction.  The data in Figure 4.2 is shown as the corrected response, where ‘corrected’ 
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means that the response of the reference flow cell is subtracted from that of the active flow cell 
(Fc2-Fc1). Initially, the solution CYP2D6 is injected on to the surface at a time point indicated 
by arrow 1 (Figure 4.2) and continued for 180 seconds.  The subtracted data can be fit using a 
simple 1:1 kinetic model to arrive at an association rate constant (ka) (2.78 x 104 M-1 s-1). This 
rate constant is the rate at which a complex of CYP2C9:CYP2D6 forms per second if CYP2C9 
and CYP2D6 were present in solutions at 1 M. A simple equation for this process is seen in 
equation 1. 
[CYP2D6] + [CYP2C9]    [CYP2D6:CYP2C9]          (1)    
ka
 
 
At time point 2 (indicated by the arrow labeled “2” in Figure 4.2) the CYP2D6 addition 
was terminated and from the resulting trace (180-1100 sec) is used to calculate the dissociation 
rate constant (kd). The dissociation rate constant (kd) (3.067 x 10-5 s-1) is the rate at which the 
CYP2C9:CYP2D6 complex separates into its individual components, CYP2C9 and CYP2D6 per 
second. A simple equation of this process can be seen below, in equation 2. 
[CYP2D6] + [CYP2C9]           (2)    [CYP2D6:CYP2C9]    
kd
 
 
 In addition to fitting the SPR binding curve to a model for 1:1 binding, we have also fit 
the data to a model for a heterogeneous ligand.  In this model, it is assumed that because of the 
random bonding of the protein to the surface, that two binding sites may exist on the surface of  
CYP2C9. Using the binding curve shown in Figure 4.2, we have measured the association rate of 
 
  
 121
CYP2D6 to two theoretical binding sites (ka1) (4.068 x 104 M-1 s-1) and ( ka2) (4.447 x 103 M-1 s-
1).  This model can be seen below, in equation 3. 
 
[CYP2D6:CYP2C91]    
ka1
[CYP2D6] + [CYP2C91]   
[CYP2D6:CYP2C9 ]    
ka2
[CYP2D6] + [CYP2C9 ]   22
 (3) 
 
 Moreover, we can also model the dissocation rate of CYP2D6 from the two different 
theoretical binding sites on the immobilized CYP2C9.  Using this model, we have measured the 
dissociation rate of CYP2D6 to two theoretical binding sites (kd1) (1.477 x 10-5 s-1) and ( kd2) 
(1.735 x 10-5 s-1). A model for this process is shown below, in equation 4. 
[CYP2D6:CYP2C91]    
kd1
[CYP2D6] + [CYP2C91]   
[CYP2D6:CYP2C9 ]    
kd2
[CYP2D6] + [CYP2C9 ]   2 2
 (4) 
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Figure 4.2.  SPR data obtained from a solution of CYP2D6 interacting with immobilized 
CYP2C9 (see Figure 1 for set-up). Concentrations, from lower trace upward, of CYP2D6 are 0 
nM, 5 nM, 10 nM, 50 nM, 100 nM and 500 nM.  Sensorgrams are presented as a subtracted 
response, where the response in the active flow cell (FC2) is subtracted from the blank flow cell 
(FC1). Sensorgram corresponding to 0 nM is used to correct the sensorgrams for changes in 
refractive index associated to the sample buffer.  
 
 
4.3.3. SPR Model Fitting 
 
As described above, SPR binding curves can be fit to several different models of 
ligand/analyte binding.   A kinetic model is generated based on experimental data, and the level 
of “fitness” of the curve is determined by a residual plot, shown in Figure 4.3.  In Figure 4.3, the 
data from the experimental traces (black triangles, gray squares) is compared to a computer 
generated kinetic model (solid black line).  As the experimental data deviates from the model at a 
given point, the response is measured to give a value for the change in response (Δ response = 
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model response - experimental response).  Models that acceptably fit the computer generated 
model have deviations of less than ± 25 RU (black boxes). Models which do not acceptably fit 
the experimental data generally have deviations fo greater than ± 25 RU (gray triangles), and 
may give poor results regarding kinetic modeling.  
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Figure 4.3.  Residual plot of kinetic fit models.  An example of a poorly fit model is shown (gray 
squares), as well kinetic model which is well fit to the data (black triangles).  The horizontal line 
at the y-axis origin (Model Fit) represents the computer generated model response to which SPR 
binding curves are fit.   
 
 
4.3.4.  Metabolism of Flurbiprofen with Immobilized CYP2C9 
 The ability of immobilized CYP2C9 constructs to metabolize flurbiprofen, a non-
steroidal inflammatory drug, has been studied.  In Figure 4.4 is shown the amount of metabolite 
formed from Au-SAM-CYP2C9 under various conditions.  Here it can be seen that the 
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metabolism of flurbiprofen requires both NADPH and cytochrome b5 (black bar) (18.37 ± 2.33 
ng), and that the presence of both of these components produces significantly more metabolite 
than if either component is missing from the incubation.  Incubations which have omitted 
NADPH (grey bar) produce very little metabolite (1.32 ± 0.13 ng).  While, incubations 
containing NADPH but no cytochrome b5 yield very little metabolite produced (white bar) (1.50 
± 0.49 ng), indicating that cytochrome b5 is necessary to shuttle a second electron to the heme 
center of immobilized CYP2C9.     
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Figure 4.4.  Effect of b5 composition on metabolic activity of CYP2C9.  All chip incubations 
contained CYP2C9, CPR, and flurbiprofen.  Chip immobilized mixture were comprised of gold 
chips with the indicated SAM, bound (OT and EG3) or bonded ((3:1) OT:MUA) CYP2C9, 
flurbiprofen, CPR and NADPH.   
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4.3.5.  Effect of Increasing Concentrations of CYP2D6 on the Metabolism of Flurbiprofen 
by Immobilized CYP2C9. 
 Several different concentrations of CYP2D6 were added to incubations containing 
immobilized CYP2C9 bearing gold chips, Figure 4.5. The calculated concentration of CYP2C9 
present on a chip using an identical method of preparation is approximately 0.5 pmol71, and 
serves as a reference point for the treatment of CYP2D6.  CYP2C9 chips containing no CYP2D6 
produced approximately 18.37 ± 2.32 ng 4’OH-flurbiprofen.  Subsequent incubations where the 
ratio of (CYP2D6:CYP2C9) was increased produced 16.15 ± 1.05 ng (0.3:1), 20.51 ± 1.53 
ng(0.5:1), 18.55 ± 1.53 ng (1:1) and 17.10 ± 1.53 ng (2:1) and show no significant difference 
from the control which contains no CYP2D6. 
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Figure 4.5.  Effect of solution CYP2D6 on the metabolism of flurbiprofen by CYP2C9.  Chip 
incubations contained CYP2C9, CPR, cytochrome B5 and flurbiprofen.  Incubations containing 
solution CYP2D6 contain(.75 nM (0.3:1)), (1.25 nM (0.5:1)), (2.5 nM (1:1)) and (5 nM (2:1)) 
respectively. 
 
 
4.4.  Discussion 
 
 Cytochrome P450 enzymes have been characterized as an essential class of heme-
containing enzymes responsible for the metabolism of a large number of pharmaceuticals. 
Typically, within the liver, cytochrome P450 enzymes are bound to the endoplasmic reticulum of 
hepatocyte cells and several different isoforms are expressed within these cells. As a result, 
protein-protein interactions between isoforms of P450 enzymes may play a role on the catalytic 
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activity of a given P450 enzyme.  The exact nature of how protein-protein interactions occur, and 
the effect of the interaction on the catalytic activity both in-vitro and in-vivo is still unclear. 
 Several different in-vitro models have been utilized in an attempt to characterize P450 
protein-protein interaction in-vivo.   A commonly used method to study these interactions is to 
use reconstituted incubations, which combine recombinant P450s, CPR, phospholipids and 
NADPH to generate a “simulated” microsomal system, capable of metabolism. These systems 
have been used to conduct mixed enzyme incubations which contain at least two different P450 
enzymes.  Interaction between P450 enzymes is often determined by an effect on the catalytic 
activity of one or more of the P450’s which are present in the system.  
The use of gold immobilized CYP2C9 also provides a platform to characterize 
biophysical interaction using SPR spectroscopy. Typically, SPR experiments are carried out on 
CM5 chips, which contain a carboxy-methyl dextran gel on the surface of a thin (50 nm) gold 
film.  Imaging of a CM5 surface with an immobilized P450 to characterize the state of 
aggregation may prove to be difficult.  The “soft” and inconsistent nature of the commercially 
available CM5192, could make it extremely difficult to characterize monomeric P450 structures 
on a surface. In contrast, by using an similar method to immobilize CYP2C9 to an OT/MUA 
SAM70, it is likely that P450 enzymes immobilized on the surface as described in the SPR 
immobilization experiment, exist in monomeric form, which can be determined by other methods 
(e.g., AFM).  
SPR spectra in Figure 4.1 suggests the formation of an OT-MUA-CYP2C9 construct 
analogous to the construct presented in the literature70,71. Moreover, this data indicates that the 
OT-MUA SAM is capable of covalently bonding CYP2C9.  Prior to this, evidence suggesting 
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the formation of a covalent bond between CYP2C9 and the SAM had been presented using x-ray 
photoelectron spectroscopy (XPS). XPS can characterize the type of bonds present on a surface 
and it was suggested that the disappearance of a peak at ~289 eV corresponding to electrons 
from a carboxylic carbon and would be replaced by an amide bond after linking CYP2C9 to the 
SAM, suggest the protein is covalently bonded71. However, the enzyme would contain identical 
carboxylic carbons, thus it would be difficult to conclusively determine if the disappearance of 
the electron peak associated with the carboxylic carbon from MUA-NHS esters truly 
disappeared, or if the peak obscured by the signal produced in the XPS spectrum of covalently 
bonded CYP2C9. 
Additionally, the use of SPR has allowed for the determination of biophysical interaction 
constants between immobilized CYP2C9 and solution CYP2D6.  After thorough searches of the 
literature, this is believed to be the first use of SPR based biosensors to characterize the 
interaction between two different P450 enzymes. Furthermore, these SPR based experiments can 
be tailored to observe interaction between virtually any P450 and can also be used to describe 
interactions that are heteromeric in nature but homomeric as well.  Characterization of 
homomeric interactions may prove to be useful in elucidating the effects of aggregation in P450 
enzyme incubations containing single P450 enzymes. 
Kinetic evaluation of protein-protein interactions using SPR spectroscopy has recently 
become an indispensable tool for biochemists. Initially, derivation of equations regarding kinetic 
rate constants characterizing protein-protein interaction was accomplished using antibody-
antigen interactions. Using rate constants modeled from subtracted SPR spectra probing 
interaction CYP2C9 and CYP2D6, in a 1:1 binding model, the quotient of the dissociation rate 
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(kd) (3.067 x 10-5 s-1) divided by the association rate (ka) (2.78 x 104 M-1 s-1) represents a 
dissociation constant (KD) of 1.10 x 10-9 M. Additionally we have also fit the model to a ligand 
containing two theoretical binding sites, know as a heterogeneous ligand binding model. The 
dissociation constant of each individual binding site is calculated by taking the quotient of the 
dissociation rate (kd1) (1.477 x 10-5 s-1) and ( kd2) (1.735 x 10-5 s-1) over the association rate (ka1) 
(4.068 x 104 M-1 s-1) and ( ka2) (4.447 x 103 M-1 s-1).  The dissocation of each binding site was 
calculated at (kD1) (3.631 x 10-10 M) and (kD1) (3.9 x 10-9 M).  Fitting of both the 1:1 binding 
model and the heterogeneous ligand binding model to residual plots found that the experimental 
data, from both models, was inside the threshold of ± 25 RU.  The poorly fit model in Figure 4.3 
may be a result of the difference in refractive index of the solution being injected onto the 
surface, compared to the refractive index of the running buffer.   
Interestingly, dissociation constants (KD) characterizing P450:CPR interactions193 of 
P450 enzymes commonly utilized in drug metabolism (CYP3A4, CYP2D6, CYP2C19) ranges 
from 5-100 nM. The experimentally derived rate constant probing for interaction between 
CYP2C9 and CYP2D6 demonstrate a dissociation constant which is 5-100 times smaller than 
dissociation constants characterizing interaction between P450 and CPR, lending further 
credence to the idea that P450 based protein-protein interactions may be playing a key role in 
metabolism.    
However, the SPR experiment described within the text is not without its limitations.   
SPR experiments can typically be used to describe dissociation constants from anywhere from 
10-5 to 10-9 M.  P450 based protein-protein interactions have been shown to have sub nano-molar 
dissociation constants,65 and, as a result, SPR may be incapable of characterizing some 
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interactions. Moreover, purified enzymes used in this experiment have exposed membrane-
associated domains, which may artificially lower the dissociation constant measured.  To counter 
this, SPR sensors can be made with a variety of different surface chemistries, capable of 
supporting artificial membrane bi-layers or liposomes.  These approaches have the potential to 
provide some insight into the role of membrane or phospholipids on protein-protein interaction 
between P450 enzymes.     
Reconstituted incubations provide the distinct advantage of being easy to modify to a 
variety of conditions and enzyme mixtures. The availability of different P450 isoforms has 
further been increased through the use of recombinant DNA technology.  However, reconstituted 
incubations of P450 enzymes are prone to enzyme aggregation, and this aggregation often 
exhibits significant effects on the catalytic activity of an enzyme.  Moreover, classical methods 
to reduce protein aggregation, including mutation of the enzyme and use of detergents to break 
up aggregates, may affect the activity of the enzyme. Ideally, it would be useful to design a 
system where the aggregation of P450 enzymes could be controlled and interactions could be 
observed using proteins interacting in a true 1:1 manner.  
To solve this question, and to provide more insight into P450 based protein-protein 
interaction, gold-immobilized enzymes present a reasonable way to control and to observe 
protein-protein interactions of monomeric enzymes. By immobilizing the enzyme to a gold 
surface, it has been demonstrated that monomeric enzymes tend to form on the surface of 
interest70.   Previous research has shown the interaction of solution CYP2D6 with gold-
immobilized CYP2C9 suggests that higher concentrations of CYP2D6 may be inhibiting the 
metabolism of Δ-9-tetrahydracannibinol194.  By using an analogous study design here, we present 
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data suggests that increasing concentrations of CYP2D6 in the presence of immobilized CYP2C9 
does not significantly affect the metabolism of flurbiprofen by CYP2C9. This data may imply 
that the effect of protein-protein interactions on catalytic activity may be substrate dependent, 
further complicating the issue of P450 protein-protein interaction. 
In contrast, solution experiments probing for interactions between CYP2C9 and CYP2D6 
show that increasing concentrations of CYP2D6 (relative to CYP2C9), may serve to inhibit the 
metabolism of flurbiprofen by CYP2C981.  This is in disagreement with the data presented using 
gold-immobilized CYP2C9 (see Figure 4.5). It is conceivable that the effect observed with 
reconstituted solution incubations is an artifact of the conditions of the incubation.  Aggregation 
in P450 enzymes may be occurring in solution, and the presence of a second P450 enzyme may 
be causing the formation of catalytically deficient mixed-enzyme aggregates.  However when the 
enzyme is in monomeric form, the effect of CYP2D6 is not a pronounced and the formation of 
large aggregates of CYP2C9 is inhibited. As a result, the catalytic activity of CYP2C9 remains 
largely unaffected. 
Here we have described a method to characterize the activity of gold –immobilized P450 
enzymes using a well characterized preparation method designed to keep P450 enzymes in 
monomeric form.  This gold-immobilized platform may be useful in elucidation of protein-
protein interaction as it occurs with monomeric P450 enzymes.  Moreover, the method of 
preparation for the formation of gold immobilized P450 enzymes can be analogously applied to 
SPR experiments to elucidate biophysical rate constants to better describe the interaction 
between different P450 enzymes. In turn, we believe that the model presented here may prove to 
provide better insight in predicting in-vivo drug metabolism using in-vitro models.  
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5.1.  Summary and Future Directions 
 
5.1.1.  Summary 
 
In Chapter 2 the use of immobilized Cytochrome P450 (CYP2C9) in PMMA based bioreactors 
was described.  Several parameters using 4 mm x 6 mm PMMA chips were optimized, including 
the concentration of enzyme used during attachment, enzyme attachment time, and the 
attachment method used for enzyme immobilization.  In exploratory studies, it was found that 
treating PMMA chips with 100 nM CYP2C9 for 24 hours resulted in the highest levels of 
metabolite. Immobilization of CYP2C9 by coordination to nickel cations chelated by 1-acetato-
4-benzyl-triazacyclononane (Acbztacn)(carboxy-terminus), was found to produce higher levels 
of metabolism as compared to N-hydroxysulfosuccinimide (NHS) and N-(3-
dimethylaminopropyl)-N’-ethyl-carbodiimide hydrochloride (EDC) covalently bonded CYP2C9 
(amino-terminus).   
 Once the optimal parameters were determined with PMMA chips, a plug-flow bioreactor 
was fabricated from PMMA in which a serpentine channel was milled.  The optimized 
parameters from the exploratory were used for CYP2C9 attachment to the channel, NADPH, 
CPR and substrate were then pumped through the channel and fractions collected.  Studies 
designed to optimize the production of metabolite found that static application of CYP2C9, 
following EDC-NHS activation of the PMMA channel produced the highest levels of metabolite.  
However, overall production of 4’-hydroxydiclofenac was considerably lower than the amount of 
compound needed to be able to conduct metabolite toxicity experiments.  
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 As an alternative to the plug-flow bioreactor, an electrochemical based system was 
studied. In this system an EDC-NHS immobilized CYP2C9 electrode was used as the working 
electrode and when current is supplied to this electrode in the presence of a CYP2C9 substrate, 
metabolite may form. This system was used to generate a CYP2C9-mediated metabolite of 
warfarin, 7-hydroxywarfarin.  At the scale used, this bioreactor produced only nanogram 
quantities of metabolite. However, based on the amount of enzyme present on the surface of the 
electrode, the system is very efficient. Moreover, the electrochemically based system requires no 
CPR or NADPH, reagents which are expensive and can become cost prohibitive, as in the case of 
the plug-flow PMMA bioreactor. Furthermore, several parameters could be optimized for the 
electrochemical batch bioreactor, including electrolysis running time, CYP2C9 electrode surface 
area and parameters to improve mass-transfer at the electrode interface could be easily modified 
to generate more metabolite, thus providing an efficient method to produce large quantities of 
metabolites for toxicity studies. 
 Chapter 3 described the fabrication of a device designed to reduce aggregation of 
Cytochrome P450 enzymes.  It has been well established in the literature that P450 enzymes 
have a strong tendency to aggregate together, and this aggregation may affect the catalytic 
activity of a P450 enzyme, ultimately altering the kinetics of P450 metabolism. As fabricated, 
this device contained small (100 nm) “nano-beakers” designed to bind P450 enzymes in them at 
a discrete point on the surface of interest. Areas surrounding the nano-beaker were covered with 
poly-ethylene glycol (PEG) moieties that resist the adsorption of the protein to the areas between 
the nano-beakers.  
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 The interaction of CYP2C with several self assembled monolayers (SAM) has been 
studied including octanethiol and (11-Mercaptoundecyl)tri(ethylene glycol) on gold and N-
octyltrimethoxysilane and 2-[Methoxy(polyethyleneoxy)propyl] trimethoxysilane on silicon 
dioxide. The interaction between CYP2C9 and these surfaces has been monitored, in real time, 
with surface plasmon resonance spectroscopy.  The results show a strong tendency for PEG 
SAMs (2-[Methoxy(polyethyleneoxy)propyl] trimethoxysilane and (11-
Mercaptoundecyl)tri(ethylene glycol)) to resist CYP2C9 adsorption, while hydrophobic SAMs 
(octanethiol and N-octyltrimethoxysilane) tend to non-specifically adsorb CYP2C9.  Moreover, 
we have also demonstrated similar interaction between CYP2C9 and our SAMs of interested 
using x-ray photoelectron spectroscopy (XPS).  This differential adsorption was used to support 
the claim that CYP2C9 was bound in the nano-beaker and not the surrounding surface. 
 Ultimately, it would be ideal to further optimize the fabrication of the nanostructure 
device to form discrete binding points which are similar in size to a Cytochrome 
P450:Cytochrome P450 Reductase (CPR) redox complex (15-20 nm). This will allow for 
unequivocal control of the dispersal of P450 enzymes from large aggregates to monomeric 
structures. This will require advances in the fabrication techniques used to make the nano-
beakers so that the dimensions can be reduced from 50-100 nm to 15-20 nm.  In turn, a device 
with appropriate sized nano-beaker may provide results that will lead to better predictions of in-
vivo drug metabolism based on in-vitro measurements. 
 In Chapter 5, surface plasmon resonance spectroscopy was utilized to measure on- and 
off-rate kinetics of binding between CYP2C9 and CYP2D6, by using a construct similar to one 
presented in the literature. SPR based biosensors provide the means to measure protein-protein 
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interactions in label free systems, and here we report one of the earliest instances of using SPR to 
measure protein-protein interactions between two P450 enzymes.  Interestingly, we found a 
dissociation constant for a 1:1 complex of CYP2C9-CYP2D6 to be approximately 1.10 nM.  The 
measurement of dissociation constants for CYP2C9-CPR is approximately 2.3 ± 1.0 nM, 
indicating a propensity for protein-protein interactions between P450 enzymes and may be 
playing a key role in the catalytic activity of a given enzyme. 
 In addition to looking at protein-protein interaction on an octanethiol 
mercaptoundecanoic acid self-assembled monolayer, we also looked at the effect on metabolic 
activity of an immobilized CYP2C9 by solution CYP2D6.  Previous reports suggested that 
increasing concentrations of CYP2D6 in the presence of immobilized CYP2C9 causes an 
increase in the metabolism of Δ-9-tetrahydrocannibinol.  Interestingly, repeating an identical 
experiment but with flurbiprofen as the substrate suggests that CYP2D6 does not modulate 
CYP2C9 activity, as increasing CYP2D6 concentrations produce no significant change in 
metabolite production.  Moreover, this finding also suggests that protein-protein interaction may 
be substrate dependent, further complicating the issue of elucidating the effects of these protein-
protein interactions. 
 In contrast, solution studies using mixed-enzyme reconstituted incubations containing 
CYP2C9-CYP2D6 suggest the presence of increasing concentrations of CYP2D6 causes a 
decrease in flurbiprofen metabolism81. It is hypothesized that aggregation in P450 enzymes can 
often modulate the catalytic activity of a given P450, and, in solution, incubations containing 
enzyme mixtures of CYP2C9 and CYP2D6 may produce catalytically deficient mixed-enzyme 
aggregates.  This implies that solution experiments may poorly model protein-protein 
 
  
 137
interactions in-vivo. In contrast, experiments containing immobilized enzymes significantly 
reduce the aggregation state of CYP2C9. As a result, the formation of mixed enzyme aggregates 
is reduced, and the inhibitory effect of CYP2D6 is no longer observed.  
5.1.2.  Future Directions 
In future experiments, it would be interesting to further characterize the interaction of 
several different P450 enzymes with each other, using a similar approach to the one described in 
chapter 4. The use of SPR based sensors will allow for the elucidation of association constants 
for P450s. Additionally, SPR provides a reasonable model to elucidate the effect of incubation 
conditions (enzyme mutation or increased detergent concentrations) on protein-protein 
interactions. Furthermore, the use of immobilized monomeric enzymes can be tailored to study 
protein-protein interactions between virtually any pair of P450 enzymes, to determine if 
aggregation may be playing a role in protein-protein interactions in mixed enzyme reconstituted 
incubations. In particular we would like to elucidate interactions between immobilized CYP2D6 
and solution CYP2C9, which in solution demonstrate no effect in the metabolism of 
dextromethorphan in the presence of increasing concentrations of CYP2C9.  Preliminary results 
suggest that previously reported solution effects are different from the corresponding 
immobilized system.  
 In addition to elucidating effects of protein-protein interaction in mixed enzyme 
incubations, it would be interesting to further characterize the effect of P450 enzymes using 
nanostructure devices similar to the one presented here. Ideally, the dimensions of the nanowell 
would be reduced to the point where we could selectively bind monomeric P450 enzymes. This 
provides a potential approach to unequivocally control of P450 aggregation.  
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The construction of the nanowell device has also lead to the potential to use the 
nanostructure device in SPR experiments.  As designed the nanostructure device contains a 
silicon dioxide layer on top of 100 nm thin films of gold.  By producing microscope cover slides 
with 50 nm of gold layers and then covering them with the patterned silicon dioxide film, one 
could use this to measure binding kinetics of monomeric P450 enzymes to clarify P450 based 
protein-protein interactions.  Moreover, the nanostructure device could be used to prepare a 
membrane bilayer195 on top the gold-thiol well described in Chapter 3, creating a solid state 
Nanodisc®-like structure with which one could measure not only protein-protein interactions, 
but protein-membrane association as well.   
Applications analogous to this idea extend beyond just P450 enzymes, as the formation of 
discoidal structures on SPR films may provide insight into monitoring protein-protein 
interactions and ligand screening for membrane bound receptors.  These receptor types include 
G-protein coupled receptors, which have demonstrated a high propensity to be targets for 
pharmaceutical compounds.  
 
5.2.  Conclusions  
 The platforms described here serve to provide some insight into issues related to solution 
P450 incubations.  Typically, solution-based P450 assays are used in the early drug development 
process to predict in-vivo drug metabolism using in-vitro models. However many of these 
models ignore issues of enzyme aggregation or protein-protein interaction between P450 
enzymes. This may result in poor predictions of in-vivo drug metabolism which may lead to 
failed investigational compounds. Presented within the text are models of P450 metabolism 
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which will address the affects of aggregation of P450 as well as protein-protein interactions in 
reconstituted P450 systems, and may serve to make improved predictions regarding in-vivo drug 
metabolism in the future.  
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